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Abstract
The serotonin type-3 receptor (5-HT3R) is a cation conducting ligand gated ion channel 
that mediates fast synaptic transmission. The 5 -H T 3R belongs to the Cys loop 
superfamily o f  ligand gated ion channels that also includes the nicotinic acetylcholine, 
glycine and GABAa receptors. The 5-HT3R has been implicated in several processes 
such as emesis, gastrointestinal motility, drug abuse, alcoholism and nociception. Studies 
involving the ligand-binding domain will thus aid in development o f new drugs that 
modulate these physiological and pathophysiological processes. The ligand-binding site 
o f this receptor is comprised o f six putative loops, viz. loop A-F. The focus o f this thesis 
was to study the interactions o f both agonists and antagonists with the 5-HTiR. 
Interactions o f two agonists, 5-HT and mCPBG, with the loop С region o f the receptor 
were studied employing biochemical and receptor m odeling studies. These studies 
identify novel determinants o f 5-HT and mCPBG interactions with the 5-НТз receptor. 
Similar studies involving granisetron, a competitive 5-HTjR antagonist also reveal novel 
amino acids that interact with this antagonist. In order to further understand antagonist 
interactions with this receptor, the approach o f structure activity relationship (SAR) 
studies was also employed to study the functional group interactions o f lerisetron, a novel 
5-HT3R antagonist. Taken together with data from loops A, B, D and E, these data reveal 
an emerging picture o f  ligand interactions with the 5 -HT3R,
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1Chapter 1: Introduction
1.1 Ion channels:
Ion channels are critical for maintaining the physiological milieu o f  every cell in 
the body. These integral membrane proteins form a pore that spans the membrane lipid 
bilayer. Their function is diverse, from being responsible for cellular excitation (brain and 
muscle) to being responsible to salt homeostasis. M ore than 100 genes coding for 
subunits o f  ion channels have been identified so far. The role o f ion channels in 
membrane excitation is as crucial as the role o f enzymes in cellular metabolism. The 
opening and closing o f  specific channels cause changes in membrane potential and lead 
to characteristic electrical messages such as inhibitory/excitatory signals and graded 
potentials.
Structure determination for ion channels is a critical component in the elucidation 
o f drug-receptor interactions and also, in understanding the pathophysiology o f diseases. 
(Barrantes, 1997; Celesia, 2001; Celesia, 2003). Structure elucidation is also critical for 
advances in lead development and rational drug design.
1.2 Classification o f ion channels:
An illustration o f different ion channels and their topologies is provided in Figure
1.1. Ion channels can be broadly classified into four m ajor classes:
1.2.1 Voltage-gated ion channels:
Voltage-gated channels sense the transmembrane potential, open or close in 
response to change in voltage (depolarization or hyperpolarization) and shape the action
potential. Types o f  voltage-gated ion channels are potassium, calcium, sodium and 
chloride channels. Potassium channels are comprised o f  a pore-form ing tetramer of 
a  subunits, which associate with accessory P subunits that are regulatory in nature 
(Hanlon and W allace, 2002). Each a  subunit contains six transmembrane segments, S l- 
S6, along with intracellularly located N and С termini (Kamb et al., 1987). The ‘P ’ 
region, which appears to be involved in conferring the К  selectivity is located between 
transmembrane segments S5 and S6 (Kamb et al., 1987). The К channel is the only ion- 
selective channel for which an a  subunit structure has been crystallographically solved 
(Doyle et al., 1998). In case o f calcium channels, as many as five subunits may form the 
channel: a l , P, a2 5 , and y. Similar to К channels, the a l  subunit is the pore-forming 
component and contains the gate and voltage sensor. The P subunit is cytoplasmic and 
plays a regulatory role. The a26  subunit o f calcium channels consists o f a cytoplasmic a2  
fragment linked to the membrane via a disulfide bond to a transmembrane 5 fragment. 
Similar to the К  channel, the pore-forming component o f the Ca channel is comprised 
o f four domains. In a Ca2* channel, however, instead o f  four separate subunits, these 
segments are derived from a single polypeptide chain, i.e, the a l  subunit, and are 
designated domains I-IV (Figure 1.1). Each highly homologous, but non identical, 
domain consists o f six transmembrane segments and is linked to the next domain by an 
intracellular loop region. As with the Kv channel, the pore is comprised o f a total o f eight 
transmembrane segments, two (S5 and S6) contributed by each domain. The a  subunit of 
Na channels has the same topological arrangement as Ca" channels. Ten different 
genes, SCN1A to SCN10A, are known to encode four-domain alpha subunits o f voltage-
gated sodium channels. M ultiple types o f alpha subunits have been cloned (Malo et al., 
1994). One or two modulatory p subunits are present in most Na channels (Catterall, 
1986). Similar to Ca channels, the Na channel is comprised o f four homologous 
domains (I-IV), each consisting o f six transmembrane segments (S1-S6), all domains 
coming from the same polypeptide chain. Similar to Ca channels, the pore is formed 
from four different P regions located between S5 and S6 in each domain (Yellen et al.,
1991). Although a low resolution cryo-electron microscopy map is available (Sato et al., 
2001), to date, no molecular structure o f a Na channel has been crystallographically 
solved. Nine different human genes encoding voltage-gated chloride channels have been 
identified (CLCN1 to CLCN7; C LC N A B ). These genes encode channels CLC1 to 
CLC7, CLCKA, and CLCKB, which do not structurally resemble any other ion channel 
family. They do not contain any charged segments such as S4 segments o f voltage-gated 
Na+, Ca and К channels. A combination o f  glycosylation and electrophysiological 
experiments on mutant proteins has revealed that both N H 2 and COOH terminals are 
located intracellularly and that the S8-S9 interlinker is extracellular because o f a 
glycosylation site.
1.2.2 Inward rectifier K+ (IRK) channels:
IRK channels possess a basic channel-forming structure with only a P domain, as 
shown for other voltage-gated ion channel members. The P domains o f  IRK channels 
exhibit limited sequence similarity to those o f other voltage-gated ion channels. They are 
also comprised o f two flanking transmembrane spanners and can form homo- or 
heterooligomers. IRK channels are designed to allow more К flow into the cell than out.
Their voltage-dependence may be regulated by external К , internal M g2", internal ATP 
and/or G-proteins (Lu, 2004). Inward rectifiers play a role in setting cellular membrane 
potentials. The closing o f these channels upon depolarization allows long duration action 
potentials with a plateau phase. Inward rectifiers do not contain the intrinsic voltage 
sensing helices that are found in voltage-gated ion channels (Figure 1.1).
1.2.3 Gap junction channels:
Gap junctions are special intercellular channels that connect the cytoplasm o f one 
cell with the neighboring cell. These channels allow the intercellular transport o f ions and 
small m olecules without leakage into extracellular space. M any gap junctions cluster 
together to form ‘plaques’ and bridge the gap between two close neighboring cells. 
Purves et al. (2001) reported that six connexin subunits from each cell join to make an 
aqueous pore connecting such neighboring cells, leading to formation o f a 12 subunit 
tube. Gap junction channels do not resemble any other known ion channels. Each 
connexin subunit has 4 transmembrane domains with extracellular loops that determine 
which connexin subtypes it joins from the next cell.
1.2.4 Intracellular ligand-gated ion channels:
Intracellular ion channels are located on cell organelles and akin to extracellular 
ligand-gated ion channels; they perform functions inside the cell. These channels are 
difficult to characterize electrophysiologically, since they are intracellularly located. 
Therefore, relatively less is known about intracellular ion channels. Various intracellular 
ligand-gated ion channels include the CFTR (cystic fibrosis transmembrane conductance 
regulator), ATP-sensitive К  channels as well as ion channels involved in sense
perception. These are often activated indirectly by G-protein coupled receptors. Other 
common intracellular ligands which activate intracellular channels include calcium ions, 
ATP, cyclic AM P and GM P as well as phosphatidyl inositol (PI).
1.2.5 Extracellular LGICs (ligand-gated ion channels):
This family is comprised o f the nicotinic acetylcholine (nAch), serotonin type-3 
(5-НТз), glycine (Gly) and y-aminobutyric acid (GABAa) receptors. This family is also 
called as the ‘C ys’ loop ligand-gated ion channel superfamily due to the presence o f a 
characteristic disulfide bond located in the extracellular domains o f  these receptors 
(Figure 1.1.5). All members o f this family are pentameric and can form either homo- or 
heteromeric receptors (A detailed description o f characteristics o f  this family is provided 
below).
Two other gene families; cation selective glutamate receptors (GluR) and the 
ATP/purinergic nucleotide receptors (P2XR) are also ligand-gated receptors, but are not 
evolutionally related to the Cys-loop family o f ligand-gated ion channels. These receptors 
differ from the nAChRs in the folds o f their peptide chains and in the number o f subunits 
that form the channel. The GluRs are tetrameric and the exact number o f subunits in 
P2XRs has not been determined so far.
1.3 The Cys-loop LGIC (ligand-gated ion channel) family:
1.3.1 Physiological role:
The Cys-loop family of ligand-gated ion channels (LGICs) plays a critical role in 
mediating fast synaptic transmission in the body. These channels are less selective and
allow two or more types o f  ions to pass through the channel pore, in contrast to voltage- 
gated ion channels which shape the action potential by typically allowing only one type 
o f ion. After the propagation o f an action potential to the presynaptic terminal, 
neurotransmitters such as acetylcholine are released via synaptic vesicles into the 
synaptic cleft. Binding o f the neurotransmitter (ligand) to the corresponding LGICs 
causes channel opening and a fast postsynaptic response that typically last only a few tens 
o f milliseconds or less. The postsynaptic response can be either inhibitory or excitatory 
depending upon the ion permeability o f the LGIC. GABA and glycine receptors are 
inhibitory because their channels are permeable to СГ; whereas 5-НТз and nAChRs are 
excitatory due to their cation permeability.
1.3.2 M ultiple subunit types:
All members o f this family form homo- or heteropentameric receptors. 
Multiple subunits (more than 2) have been cloned for all members o f this family. For 
example, ten a  subunits ( a l - a lO )  and four p subunits (p l-p 4 )  have been cloned for the 
nAChR. O f these, a 2 -o tl0  and P2~P4 are neuronal subunits, while a l  and p i are muscle 
subunits (Am eric and Brioni, 1999). The assembly o f  different subunits in different 
stoichiometries forms receptors with different pharmacological and biophysical 
properties. Depending on age or their location in the body, nAChRs vary in their subunit 
compositions (Gu and Hall, 1988a; Gu and Hall, 1988b). M uscle nAChRs are either 
0C2py8 (fetal) or агРеб (adult) while neuronal nAChRs are composed o f a  and P subunits 
(Mishina et al., 1986). Similarly, various subunits (а , P, 8,y, p) o f  the GABAa R have 
been cloned and their biophysical characterization has shown that multiple subunits can
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combine to give multiple receptor subtypes. Only heteropentameric GABA aRs are found 
in the body (Enna and Bowery, 1997). The glycine receptor consists mainly o f  a  and p 
subunits and at least 2 a  and P subunits have been cloned so far. These subunits assemble 
as homo or heteropentameric glycine receptors in the body (Zafra et al,, 1997).
1.3.3 M embrane topology and architecture:
The membrane topology o f the Cys-loop family o f LGICs is shown in Figure
1.1.5. Based on hydrophobicity plots and sequence homology, all members o f  this family 
are purported to contain a large N-terminal domain, a transmembrane region which spans 
the membrane four times (forming M1-M4 domains, 2 intracellular and 1 extracellular 
loop) and a short С-terminal region. A characteristic Cys-Cys disulfide bond is present in 
the N-terminal region o f all members o f this family. Five such subunits coassemble to 
form a pentameric ion channel, wherein the М2 region from each subunit contributes to 
the channel pore (as shown in Figure 1.1.6).
1.3.4 Examples of ligand-gated channelopathies:
ACh receptor channelopathies include autosomal dominant frontal nocturnal 
epilepsy, congenital myasthenia gravis syndromes, familial infantile myasthenia gravis, 
myasthenia gravis, neonatal transient and endplate acetylcholinesterase deficiency 
(Celesia, 2001). Defects in nAChRs or their loss can also contribute to A lzheim er’s and 
Parkinson’s diseases and schizophrenia. Glycine receptor channelopathies include 
hyperekplexia (familial startle disease) and spastic paraparesis (Celesia, 2001). Mutations 
o f the У2 GABAa subunit are found in families affected by febrile epileptic seizures
(Celesia, 2003). No naturally occurring mutations or channelopathies have been reported 
so far for 5-HT?Rs.
1.4 5-Hydroxytryptam ine (Serotonin) type 3 receptor [5-HT3Rj:
This thesis focuses on the 5 -HT3R. The murine 5-HT3AR was cloned in 1991 from 
N1E-115 neuroblastoma cells by M aricq et al. (Maricq et al., 1 9 9 1 ) . Five 5-HT3AR 
subunits coassemble to yield homomeric LGIC receptors. The membrane topology o f the 
5-HT3AR subunit is shown in Figure 1.1.5. The mouse 5-HT3AR is comprised o f 487 
amino acids and weighs -5 0  Kda (-65  Kda when glycosylated) (Hovius et al., 1998; 
M cKeman et al., 1990). -243  amino acids are thought to contribute to the large N- 
terminal domain. The transmembrane domain consists o f 4 regions; M1-M4. Three loops 
are thought to connect the M1-M4 regions; the M l-М2, M2-M3 and M 3-M 4 loops. O f 
these loops, the M2-M3 loop is extracellularly located. A short С-terminal domain is also 
extracellularly located. The N-terminal domain has as many as six possible glycosylation 
sites. The M 3-M 4 loop has three putative phosphorylation sites, o f  which (S414) appears 
to be phosphorylated in vivo (Lankiewicz et al., 2000). Receptor phosphorylation has 
been implicated to play a role in 5-HT3 receptor conductance levels (Van Hooft and 
Vijverberg, 1995) and desensitization rates (Hubbard et al., 2000). The М2 region lines 
the channel pore, and contributes to cation selectivity, channel gating and desensitization 
(Panicker et al., 2002).
1.4.1 Historical background about the discovery of 5-H T3RS :
It is now known that serotonin (5-HT) can activate both the fast ligand-gated ion 
channel (5-HTjR) and the slow G-protein coupled metabotropic 5-HT receptors which
include the 5-НТьг and 5-HT4.7 receptors. However, the action o f 5-HT and the 
elucidation o f putative 5-HT receptors was confusing until it was determined that 5- 
HT3RS are ligand-gated ion channels.
In 1953, Rocha E et al. reported that the contractile actions o f 5-HT in the guinea 
pig ileum are due to a discharge o f post-ganglionic cholinergic fibers (Rocha et al,, 
1953). Gaddum e and Picarelli later reported that effects o f 5-HT and tryptamine are via 
‘tyrptamine receptors’. They also proposed that 5-HT causes contraction o f the guinea 
pig ileum by acting on two types o f receptors viz., D (blocked by dibenzyline) and M 
(blocked by morphine) (Gaddum and Picarelli, 1957). The next 5-HT receptor 
classification was reported by Peroutka and Snyder. This group used radioligand binding 
assays and classified 5-HT receptors as 5-HTi (with low affinity for 5-HT) and З-НТ2 
(high affinity for 5-HT) receptors (Peroutka and Snyder, 1979). The 5-HT] receptors 
appeared similar to the D type o f  receptor proposed earlier, but neither receptor was 
similar to the M type 5-HT receptor. Studies by Fozard and M obarok later showed that 
application o f  5-HT induced tachycardia in a rabbit heart preparation and could be 
blocked by metoclopramide and (-) cocaine. This receptor was similar to the M type 
receptor (Fozard and M obarok, 1978). This observation led to the synthesis o f MDL 
72222, a very potent M receptor antagonist, which was more specific than 
metoclopramide and (-) cocaine (Fozard, 1984). More selective M -receptor antagonists 
such as tropisetron, ondansetron, granisetron and zacopride were subsequently 
synthesized (Kilpatrick et al., 1990; King, 1994; Richardson, 1995).
Bradley et al. reclassified the M type receptor as the 5-НТз receptor in 1986. 
Using localization studies and measurement o f 5-ІІТз antagonist activity, it was 
determined that in the periphery, 5-HTiRs are located on pre- and postganglionic 
autonomic neurons, enteric nervous system, neurons o f the sensory nervous system, 
somatic and vagal afferent fibers and on peripheral terminals o f vagal afferents. In the 
central nervous system, 5 -H T iR s  are located on central terminals o f vagal afferents, brain 
and spinal cord (Leslie et al., 1994; Sanger and Jones, 1994).
1.4.2 Cloning o f5 -H T 3Rs:
The first 5 -HT3R cDNA (now designated as the 5-HT3AR) was cloned from the 
murine N1E-115 neuroblastoma cell line by M aricq et al. in 1991 (Maricq et a l ,  1991). 
Two splice variants, short and long, were also cloned from neuroblastoma-glioma cell 
lines (NCB-20 and NG108-15), A second subunit, 5-НТзв was cloned by Davies et al. in 
1999 (Davies et al., 1999). Genes encoding 5-НТзс, 5-НТзо and 5-Н Т зе subunits have 
also been reported (Niesler et al., 2003).
1.4.3 Properties o f 5-HT3R splice variants and subunits:
Two splice variants o f the 5-HT3A; 5-HT3As (short) and 5-НТЗАь (long) are known 
(W erner et al., 1994). Differences between splice variants in agonist pharmacology are 
small (Downie et al., 1994; Hope et a l ,  1993), with changes seen in efficacy o f wCPBG 
and 2-methyl 5-HT compared to 5-HT. Intracellular kinases may functionally 
discriminate between the short and long variants (Hubbard et al., 2000). In addition to the 
A subunit, the 5-HT3B subunit has also been cloned from human, (Davies et al., 1999; 
Dubin et al., 19991 mouse and rat species (Hanna et al., 2000). The 5-НТзв subunits share
-45%  sequence identity with their 5-HT3A homologues, but cannot form functional 
homopentameric receptors (Davies et al., 1999). However, the 5-HT3b subunit forms 
functional 5-HT3Ab heteromers when coexpressed with the 5-НТ3д subunit. 5-HT3B 
receptor subunits have putative extracellular N-glycosylation and intracellular 
phosphorylation consensus sites comparable with the 5-HT3A subunit. The 5-HT3Ab 
heteromeric receptors are pharmacologically and functionally distinct from 5-HT3aRs. 
For example, the 5-HT3AbRs display 30 times higher conductance as compared to 5- 
HT3ARs. Three arginine residues at positions 432, 436 and 440 in the second intracellular 
loop (a region called HA stretch) have been shown to play a major role in determining 
channel conductance. These three positively charged residues are thought to hinder cation 
conduction in the homomeric receptors. This stretch is absent in the В receptors and may 
explain why the heteromeric 5-HT3ab receptors have higher conductance (Kelley et al., 
2003b). These different properties o f 5-HT3AbRs help explain the functional differences 
observed between native and recombinant 5-HT3 receptors, that could not be explained 
by existence o f  splice variants o f the 5-HT3AR.
1.4.4 5-HTjRs are centrally and peripherally distributed:
In rat, 5-HT3Rs are located in cortical and limbic areas. It has been shown that 
5HTiR-immunoreactive neurons are present in the forebrain, brainstem, dorsal and 
ventral horns o f  the spinal cord (Bloom and M orales, 1998). In rat neocortex and 
hippocampus, the majority o f 5-HT3R sare  expressed on GABAergic neurons, suggesting 
a modulatory role o f 5-HT3R in release o f GABA and it's mediation o f inhibitory 
neurotransmission (Bloom and Morales, 1908: Morales and Bloom, 1997).
In the rat, 5-HT3A and 5-HT3AB receptors are peripherally located; whereas only 
homomeric 5-HT3ARs are centrally located (Morales and Wang, 2002). In the periphery, 
5-HT3R is expressed in dorsal root and nodose ganglia, vagus nerve and intestinal 
submucosal plexus. In the rat gastrointestinal system, 5-НТзRs are localized to neurons of 
the myenteric and submucosal plexus, fibers in the circular and longitudinal muscles, 
submucosa, and mucosa (Glatzle et al., 2002).
In humans, 5-HT3Rs are located in brainstem, spinal cord, amygdala, area 
postrema (chem oreceptor trigger zone, CTZ) and hippocampus (W'aeber et al., 1989).
Both 5-HT3 A and В subunits have been detected in the human amygdala, caudate and
hippocampus (Davies et al., 1999). Expression o f 5-HT3 D and 5-HT3 E subunits is 
restricted to only three and two tissues, respectively (D- adult: kidney, colon, liver; fetal: 
colon and kidney; E- adult: colon, intestine). On the other hand 5-HT3C is more widely 
expressed (adult: brain, colon, intestine, lung, muscle, stomach; fetal: colon and kidney) 
(Niesler et al., 2003). Therefore, the expression pattern o f  5-HT3C resembles more 
closely that o f  5-HT3A and 5-HT3 В subunits.
1.4.5 Physiological role and clinical relevance of 5-HT3R:
1.4.5.1 Emesis:
5-HT3Rs located on the area postrema and nucleus solitarius are involved in 
mediating the vomiting reflex. 5-HT3R antagonists such as granisetron, ondansetron and 
palanosetron are clinically used in the treatment o f chemotherapy induced nausea and 
emesis (Aapro, 2004). These antagonists antagonize emesis produced by cisplatin, other
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emetogenic chemotherapeutic agents and by radiation therapy. These 5 -HT3R antagonists 
are thought to act by blockade o f 1) 5 -HT3RS in the area postrema and nucleus solitarius 
and 2) 5 -HT3RS present on vagal afferents in the gut (Andrews, 1994).
1.4.5.2 Female and male behavior:
It has been shown by studies in mice that knock out o f  the 5-HT? receptor 
differentially affects behavior o f males and females in the Porsolt forced swim and 
defensive withdrawal tests. The Porsolt forced swim test is used to detect anti-depressant 
efficacy, while the defensive withdrawal test is used to measure anxiety. Results from 
these studies suggest that the 5-НТз receptor regulates behavior related to depression and 
anxiety differently in males and females.
1.4.5.3 Nociception:
5-НТз receptors are important in nociceptive processing (Alhaider et al., 1991; 
Eide and Hole, 1993; Zeitz et a t ,  2002), consistent with expression on primary sensory 
afferents in the dorsal root ganglion (DRG), on neurons in the dorsal horn o f the spinal 
cord and sensory nerve endings in the periphery (Hamon et al., 1989; Kidd et al., 1993, 
Tecott et al., 1993; Kia et al., 1995; Morales and Wang, 2002; Zeitz et al., 2002). Using 
the antisense approach, the effect o f knocking out 5-HT3Rs on analgesia produced by 5- 
HT3R agonists such as 5-HT and 2-methyl-5-HT were studied. In mice tested with 
intrathecal 5-HT and 2-methyl 5-HT, tail-flick analgesia attenuated in mice treated with 
the 5-HT3R antisense oligos, suggesting a role for 5-HT3Rs in spinal antinociception.
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1.4.5.4 Anxiety:
5-НТз receptors have been implicated in C N S functions such as cognition and 
anxiety as well as sympathetic, parasympathetic, and sensory functions in the peripheral 
nervous system (P N S) (Jackson and Yakel, 1995; Johnson and Heinemann, 1995; 
Morales and Wang, 2002). Targeted gene deletion o f the 5-HT® receptor subunit 
produces an anxiolytic-like behavioral phenotype in mice (Kelley et al., 2003a). These 
anxiolytic-like effects were similar to pharmacological blockade o f  5-НТз receptors 
produced by 5 -HT3R antagonists such as ondansetron. This observation supports a role 
for 5 -HT3R in m odulation o f anxiety and is also consistent with studies concluding the 
effectiveness o f 5-HT?R antagonists in animal models o f anxiety.
1.4.5.5 Gastrointestinal motility:
5-НТз receptors on vagal sensory afferents modulate visceral afferent and efferent 
information in the gastrointestinal tract (Leslie et al., 1990; Merahi et al., 1992; Veelken 
et al., 1993; Sevoz-Couche et al., 2003). In the enteric nervous system, 5-НТз receptors 
also regulate gut m otility and peristalsis (Galligan, 2002).
1.4.5.6 Urinary function:
W ithin the lower urinary tract, presynaptic 5-НТз receptors have been implicated 
in parasympathetic transmission to the urinary bladder through neuronal acetylcholine 
(ACh) release and smooth muscle contraction (Chen, 1990; Barras et al., 1996) Recently, 
5-Н Т за mutant mice with a channel mutation (V 13’S mutation in М2 region) were shown 
to exhibit urinary dysfunction. This channel mutation has been shown to render the 5-НТз 
receptor ~70-fold more sensitive to serotonin and produced constitutive active receptors
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when coexpressed with the 5-НТзв subunit (Dang et al., 2000). These data in 
combination with the data from mutant mice suggest that persistent activation o f the 
hypersensitive and constitutively active 5-НТзд receptor in vivo leads to excitotoxic 
neuronal cell death and functional changes in the urinary bladder, resulting in bladder 
hyperdistension, urinary retention, and overflow incontinence.
1.4.5.7 Reflex bradycardia:
The 5 -HT3R is believed to play a role in the hypotension following 5-HT infusion. 
This type o f  hypotension or bradycardia is known as the von Bezold Jarisch reflex and is 
thought to be mediated by the 5 H l\R s on the vagus (Richardson et al., 1985).
1.4.6 Clinical uses of 5 -HT3R antagonists and agonists:
The traditional use o f 5-HT3R antagonists such as ondansetron has been in 
treatment o f  chemotherapy induced emesis (by targeting the 5-HT3Rs in the CTZ). 
However, recent studies have also demonstrated the usefulness o f  5-HT3R antagonists in 
the treatment o f irritable bowel syndrome (IBS), anxiety, early onset alcoholism and drug 
abuse. In a clinical trial with diagnosed alcoholics, it was concluded that ondansetron is 
an effective treatm ent for early-onset alcoholism, where patients generally respond 
poorly to psychosocial treatment alone. The use o f antagonists in alcoholism and drug 
abuse is believed to be associated with 5-HT3Rs found in reward centers in the brain. 
Tropisetron and ondansetron reduce morphine self-administration in both naive and 
m orphine-dependent rats (Hui et al., 1993). Injection o f ondansetron into the rat nucleus 
accumbens attenuates the action o f cocaine (Herges and Taylor, 2000). 5-HT3Rs in areas 
such as the nucleus accumbens are thought to be involved in prc-synaptic modulation of
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dopaminergic neurotransmission. Ondansetron has also been shown to reduce cognitive 
impairment caused by the muscarinic antagonist, scopolamine and the NM DA receptor 
antagonist, MK-801 (Costall and Naylor, 2004).
In addition to the aforesaid uses o f antagonists, 5-IIT jR  agonists also show 
promise in the treatment o f various types o f constipation, and certain other 
gastrointestinal m otility disorders including gastroesophageal reflux disease (GERD) 
(Coleman et al., 2003; Imanishi et al., 2003; Revel et al., 1999)
1.4.7 Chemical classification of 5-HTjR ligands:
The chemical structures o f various 5-НТз agonists, partial agonists and 
antagonists are shown in Figures 1.2, 1.3 and 1.4.
1.4.7.1 5 -HT3R agonists:
The major classes o f 5 -HT3R agonists (see Figure 1.2) include the following:
1. 5-HT and other 5-HT analogs such as 5-HTQ, and 2-methyl 5-HT. 2-methyl-5- 
HT is a partial agonist with -12%  relative efficacy compared to 5-HT on the murine short 
form o f the 5-HT3aR. This compound is also potent on 5-HTftRs and is therefore less 
specific.
2. Phenylbiguanides (mCPBG) and phenylguanides (/wCPG): mCPBG is a partial 
agonist o f the 5-HT3Rs. In case o f the short form o f murine 5 -HT3AR, it has -93%  
relative efficacy compared to 5-HT.
3. Piperazinylquinolines such as quipazine and its analogs,
4. M iscellaneous compounds including certain tetrahydrothiazolopyridines 
(Imanishi et al., 2003), aminoalkyl- and imidazoloalkyl-indenothiazoles (YM-31636)
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reported recently (Imanishi et al., 2003), and dihydrofurano[2,3-b]pyridine 
5 -HT3R/nACha-?R agonist PSAB-OFP (Broad et al., 2002).
1.4.7.2 5 -H T 3R partial agonists:
In addition to 2-methyl 5-HT and mCPBG discussed above, certain benzylidene- 
anabeseines and quipazine analogs (see Figure 1.2) are also partial agonists o f the 5- 
HT3R, Partial agonists are valuable tools in studying receptor gating mechanisms. 
Changes in efficacy value o f a partial agonist relative to the full agonist can provide 
valuable information about the gating mechanism (or signal transduction to open state) o f 
an ion channel. M ore detailed information about employing partial agonists to decipher 
gating effects is discussed in chapter 3.
1.4.7.3 5 -HT 3R antagonists:
Compared to 5-H T 3R agonists, extensive numbers o f antagonists have been 
synthesized because o f their clinical application for the treatment o f chemotherapy 
induced emesis. M any 5-НТз antagonists were also synthesized as pharmacological tools 
for the characterization o f the M type 5-HT receptor, which we now know as the 5-HT?R.
The original 5-НТз antagonist pharmacophore developed by Hibert et al. 
consisted o f an aromatic group, a carbonyl group and basic nitrogen, which is 1 .7A  above 
the plane o f the aromatic ring (Hibert et al., 1990). This pharmacophore has been further 
modified by contributions from various studies (Hibert et al., 1990; Rizzi et al., 1993; 
Rizzi et al., 1990; Swain et al., 1991). This revised pharm acophore is shown in Figure
1.4. Most 5 -H T 3R antagonists fit this pharmacophore. 5 -H T 3R antagonists can be 
classified as indoles (tropisteron), benzoates (MDL 72222), indazoles (granisetron),
carbazoles (ondansetron) and benzamides (zacopride). Structures o f these compounds are 
shown in Figure 1.4. Orjales et al. reported a novel benzimidazole ring containing 5- 
HT3R antagonist, lerisetron (Piperazinyl N-benzyl benzimidazole). As shown in Figure
1.5, the structure o f lerisetron fits the Hibert pharmacophore, but also contains an 
additional N1 substituent, which appears to confer increased affinity. In addition to these 
antagonists, (+)-tubocurarine (dTC), a potent nAChR antagonist, is also a very potent 5- 
HT3R antagonist. This large compound differs markedly from all other 5 -HT3R 
antagonists.
1.4.8 Ligand-binding site of the 5 -HT3R:
A cryo-electron micrograph has been determined at a 4.6A resolution for the 
nAChR (M iyazawa et al., 1999), In addition to extensive site-directed mutagenesis, 
several approaches including photoaffinity labeling, detailed single channel analysis, 
NM R studies o f  peptide fragments have been utilized to study the nAChR. Unlike the 
nAChR, most o f the information about the structure and function o f  5 -HT3R has been 
derived from mutagenesis studies.
The discovery o f the Acetylcholine Binding Protein (AChBP) has led to rapid 
developments in the understanding o f the ligand-binding site o f  LGICs. This soluble 
binding protein bears a significant degree o f sequence and structural homology to the N- 
termmal domain o f all ligand-gated ion channel receptors. This protein shares about 25% 
sequence homology with the N-terminal extracellular regions o f  Cys-loop LGIC 
receptors. The crystal structure o f the AChBP has been solved (Brejc et al., 2001).Based 
on the structure o f  AChBP, much o f the previous biochcmical data for LGIC reccptors
can now be placed in a 3-D perspective. Thus, AChBP-based homology models o f  all 
LGIC receptors have been developed. These models represent static pictures o f the 
extracellular domain and do not provide direct information about the activation 
mechanism and conformational changes that occur on ligand binding. Based on a 
combination o f previous experimental data and AChBP-based homology models, the 
ligand-binding site o f 5-HT<R (and other LGICs) is thought to be comprised o f a 
principal (+) face and a complementary (-) face. Each face o f  the binding site includes 
three loops that contribute to ligand interactions. The + face contains Loops A-С and the 
-  face contains loops D-F (See Figure 1.1.5).
1.4.8.1. Loop A residues:
E l29 o f  Loop A region has been proposed to interact with the NFL group o f the 
agonist 5-HT via an ionic or hydrogen bond interaction (This residue is designated as 
E106 according to the author’s numbering). In AChBP-based 5-HT3R homology models, 
this residue is farther than 4A o f docked ligands. Therefore, it is unclear if  this residue 
actually forms a part o f the ligand-binding site. M utation o f  F I 30 selectively alters 
electrophysiological responses to 5-HT, but not mCPBG. (This residue is designated as 
F I 07 according to the author’s numbering). Mutation o f this residue to Asparagine 
(F130N) produces receptors that can be activated by acetylcholine, suggesting that this 
residue may play a role in ligand recognition. Homology and docking studies o f 5 -HT3R 
predict that this residue is over 4A from docked ligands, indicating that this residue may 
not form a part o f the ligand-binding site. It is possible that F I 30 is important for ligand 
recognition or ligand ‘processing’ before the ligand actually enters the binding site.
1.4.8.2. Loop В residues:
Site directed mutagenesis o f all tryptophan residues in the 5 -HT3R N-terminal 
identified W183 o f  the Loop В region as a critical component o f the binding site (Spier 
and Lummis, 2000). Mutation o f this residue to either alanine or tyrosine ablated 
radioligand binding. Concomitantly, large changes in affinities o f both 5-HT and mCPBG 
were seen. Using unnatural amino acid substitutions, it has been postulated that this 
tryptophan residue forms a cation-pi interaction with the NH2 (amino) group o f 5-HT, 
i.e., the positively charged amino group o f the ligand (5-HT) interacts with the pi cloud o f 
the aromatic ring o f tryptophan. The homologous residue in the nAChR was shown to 
participate in a cation- pi interaction with acetylcholine (Beene et al., 2002; Zhong et al., 
1998). The hom ologous residue in GABA receptors has also been shown to be involved 
in ligand binding. Thus this residue is a critical aromatic residue for ligand binding in all 
members o f the LGIC family. The importance o f  this residue is also supported by 
homology and docking studies o f  LGICs. The roles o f other residues in the putative Loop 
В region have not been studied.
1.4.8.3. Loop С residues:
Residues E225, Y234 and E236 from the loop С region o f the mouse 5-HT3R 
have been postulated to play a role in the ligand binding and/or gating (Price and 
Lummis, 2004; Schreiter et al., 2003). However, the assignment o f a role in gating for 
these residues is speculative since it is based only on changes in EC50 and/or K, values 
(Colquhoun, 1998). A comparison o f unliganded and liganded crystal structures o f 
AChBP suggests that the loop С region undergoes the largest movement after agonist
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binding (Celie et al., 2004). A substituted cysteine accessibility method (SCAM) study of 
the loop С region o f the p2 GA BAaR also implicates this region in conformational 
changes after agonist binding (W agner and Czajkowski, 2001). However, a detailed 
evaluation o f the role o f each loop С residue o f the 5-HTjR in ligand binding and gating 
was unavailable prior to the presentation o f this thesis.
1.4.8.4. Loop D residues
Using alanine scanning mutagenesis o f  the putative Loop D region, Yan et al. 
showed that residues in this region differentially interact with ligands. The affinity for d- 
TC was reduced by mutations at W89, and the affinity for serotonin was reduced by 
substitution at R91 (Yan et al., 1999). On the other hand, affinity for granisetron was 
reduced by mutations at W89, R91, and Y93. Based on the ‘every-other-residue’ 
periodicity o f the effects o f  Loop D mutations on affinity for granisetron, Yan et al. 
concluded that this region o f the binding site adopts a P conformation. This structure for 
the Loop D region has now been verified by AChBP-based homology models o f the 5- 
HTjR. These models also suggest that the tertiary ammonium ions o f  antagonists interact 
with W90 via a cation-pi interaction (Maksay et al., 2003).
1.4.8.5. Loop E residues:
Using alanine scanning mutagenesis, Venkataraman et al. showed that three 
tyrosine residues (Y 141, Y143 and Y153) from the Loop E region interact with both 
agonists (5-HT, mCPBG and antagonists (d-TC and lerisetron) (Venkataraman et al., 
2002b). M utation o f  Y153 to alanine caused significant changes in 5-HT induced 
response kinetics. It was also shown that 5-HT and mCPBG interact with Y143, d-TC
interacts with Y141 and lerisetron interacts with both Y143 and Y153. Based on the 
overall data, it was suggested that this region o f the 5 -HT3R adopts a loop conformation. 
This prediction has also been verified by AChBP-based homology models o f the 5 -HT3R.
1.5 Activation of LGIC receptors:
The nAChR is the most characterized member o f the LGIC family. Quantitative 
studies o f the muscle nAChR have been possible due to the rich abundance o f these 
receptors in the electric organ o f the Torpedo ray. The structure o f the muscle nAChR 
has been elegantly studied using electron microscopy. These studies have led to 
development o f three dimensional map o f the closed form o f the receptor at 9 A and 4.6A 
levels (M iyazawa et al., 1999; Unwin, 1993). The structural transition from the closed to 
the open-channel conformation o f the receptor has been analysed at 9A resolution by 
comparing three-dimensional maps o f the closed and open conformations (Unwin, 1995). 
A detailed comparison o f the two structures indicated that the binding o f ACh initiates 
two interconnected events in the extracellular domain. The first is a local disturbance, 
involving all five subunits, in the region o f the binding sites, and the second is an 
extended conformational change, involving predominantly the two a  subunits, which 
communicates to the transmembrane portion. In the open form, the М2 transmembrane 
helices rotate and switch to a new configuration in which they point outwards instead o f 
pointing towards the axis o f the pore, as in the closed form. These experiments give a 
picture o f the receptor in closed and open-channel conformations, but do not provide any 
information about the events that lead to this transition.
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A more precise description o f the extended conformational change has recently 
been obtained by a comparing the 4.6A structure o f the nAChR extracellular domain 
with the crystal structure o f the AChBP. It was found that there are two alternative 
extended conformations o f the receptor subunits - one characteristic o f either a  subunit 
before activation (a form), and the other characteristic o f the three non-а subunits (non-a 
form). Binding o f ACh converts the structures o f the two a  subunits to the non-a form 
(Unwin et al., 2002). In the closed state, the a  subunits are initially distorted (rigid) due 
to their interactions with neighboring subunits, and the free energy o f binding overcomes 
these distortions, making the whole assembly more symmetrical and similar to the 
ligand-bound AChBP. This transition to the activated conformation o f the receptor is 
believed to involve relative movements o f the inner and outer parts o f  the P-sandwich in 
the binding site, which compose the core o f the a  subunit around the Cys-loop disulfide 
bond (see Figure 1.6). It has been suggested that these movements are translated to the 
transmembrane region via the interaction o f the Cys-loop and/or the Pi—p2 loop with the 
proximal M2-M3 extracellular loop. In GABAa and glycine receptors, it has been shown 
that such electrostatic interactions exist between residues in Cys-loop and the M2-M3 
loop and may form the trigger to channel opening. Similar interactions have not yet been 
shown in either the nACh or 5-HTjRs. In case o f 5 -HT3RS, R222 a pre-M l residue has 
been shown to be important for gating. Although the mechanism o f channel opening may 
be similar across all LGICs, there may be differences in the types o f interactions formed 
and the residues involved. In the 5-HT?R, it is unclear if  there is a Cys-loop to M2-M3
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connection, involvement o f  M l region or some other part o f  the protein in the signal 
transduction pathway.
1.6 Role of 5~H I\ В subunit in the ligand-binding site:
Although the role o f residues o f the HA stretch in the M 3-M 4 region o f the В 
subunit in contributing to the higher conductance o f heteromeric AB receptors has been 
elucidated, the contribution (if any) o f the В subunit to the binding site o f  AB receptors is 
not known. The stoichiometry o f AB receptors is also unknown. An ER retention signal 
(CRAR sequence) in the transmembrane region o f the 5-НТзВ subunit has been shown to 
play a role in intracellular retention o f the 5-НТзВ subunit. However, replacement o f this 
ER retention signal in 5-HT3B to the corresponding sequence in the A subunit (SGER) 
does not lead to cell surface expression, suggesting the presence o f other signals or 
mechanisms that control the surface expression o f 5-HT3bRs.
1.7 Overview of approaches used to study structure o f ligand-gated ion channels:
1.7.1 Electron M icroscopy of 5-HT3 receptors
Electron microscopy studies have described the 5-HT3R as a doughnut-shaped 
toroidal ring with a stain-filled center and a diameter o f  70A (Boess et al., 1992; Green et 
al., 1995). This structure is similar to the purified Torpedo ray nAChR. These results 
support a quaternary structure o f 5-HT3 receptors similar to that o f nACh and GABAa 
receptors. The eventual aim o f  the electron microscopy studies was to obtain purified 5- 
HT3R receptor in amounts sufficient to perform X-ray crystallography and structure 
determination. However, such studies have not been reported with this purified receptor.
The inability to obtain high concentrations o f pure receptor is a major hindrance in 
carrying out such detailed structural studies.
1.7.2 X-ray crystallography:
X-ray crystallography requires pure crystalline protein for structure 
determination. Structure depictions by X-ray crystallography are static and typically do 
not explain function/movements in the crystallized protein. In addition, highly 
flexible/mobile structural parts such as surface loops are often not resolved via X-ray 
crystallography. Combining high resolution structures o f proteins (obtained by X-ray 
crystallography/NM R) with electron micrographs by superposition o f the two distinct 
structures provides more insights into the protein structure.
M embrane proteins such as LGICs are difficult to crystallize since they tend to 
precipitate out o f  solution due to unfavorable protein-protein and protein-solute 
interactions. To be kept soluble in aqueous solution, membrane proteins need the addition 
o f detergents. Detergents, however, often interfere with regular arrangements o f the 
protein complexes in the crystal, resulting in a diffuse diffraction pattern. Several groups 
have attempted to truncate extracellular domains o f  large membrane-bound ion channels 
in order to obtain fragments that may be relatively easy to crystallize (as compared to the 
entire receptor). This approach has been used for the glutamate receptor, GluR2. In 
GluR2, the ligand binding domain is composed o f SI and S2 segments, which are 
separated by transmembrane segments M l, М2 and М3 in the full length receptor. 
Several recombinant ‘HS1S2’ constructs were designed wherein an N-terminal Histidine 
(His) tag was added. These constructs were engineered to produce different deletions at
the SI and S2 termini and S1-S2 linkers (Chen et al., 1998). One o f the constructs, 
‘HS1S2I’ was found to yield large amounts o f biologically active GluR2 ligand binding 
domains in E  coli cells. This construct was readily amenable to structure determination 
by X-ray crystallography in the absence and presence o f glutamate, alpha-amino-3- 
hydroxy-5-methyl-4-isoxazole-propionic acid (AM PA) and kainate. This study also 
facilitated the crystallization o f the ligand binding core o f another novel S1S2 construct 
in the apo state (absence o f ligand) and in the presence o f  the antagonist 6,7- 
dinitroquinoxaline-2,3-dione (DNQX), partial agonist kainate, and full agonists 
glutamate, and AMPA. These ligand-bound crystal structures provided the first views o f 
the ligand binding core o f a ligand-gated ion channel in distinct conformations that may 
be associated with different functional states o f the channel, thus lending insight into 
receptor activation, antagonism, and the molecular basis for ligand specificity.
Obtaining a soluble version o f an extracellular domain (ECD) for a Cys-loop 
ligand-gated ion channel has been a challenging task since these receptors are multimeric. 
The truncated S1S2 construct o f GluR2, described above, is a monomer. Similar 
truncated multimeric constructs for the Cys-loop family would be harder to crystallize 
since the binding site is located at intersubunit interfaces and it would be necessary to 
preserve all important intersubunit contacts. Attempts to obtain a truncated, crystallizable 
version o f the nicotinic acetylcholine receptor have not proven to be successful so far 
(Wells et al., 1998). Although the muscle nAChR is found in large amounts in the electric 
organ o f Torpedo ray, no X-ray crystallography data is yet available for this receptor. An 
electron microscopy map o f 4.6A is available for the nAChR (M iyazawa et al., 1999).
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1.7.3. Use o f NM R spectroscopy in structure elucidation
For structure elucidation by NMR, high concentrations o f pure, solubilized 
proteins are typically required. As discussed in the X-ray crystallography section, the 
extracellular ligand-binding (S1S2) core o f the GluR2 has been expressed in bacteria as a 
soluble, monomeric protein. Based on the ligand bound crystal structure o f this construct, 
a S1-S2 domain closure upon ligand binding was postulated, but details o f intradomain 
motions could not be investigated. Using NM R relaxation measurements on the fully 
deuterated S1S2 protein, motions o f the ligand-binding core o f GluR2 bound to glutamate 
were studied. N longitudinal (T l)  and transverse (T2) relaxation measurements as well 
as [ 'Н ]-1 N nuclear Overhauser effects at 500 and 600M Hz were measured. It was found 
that residues in the agonist-binding pocket exhibited two main classes o f  motion. Those 
contacting the a-substituents o f  the ligand glutamate exhibited minimal internal motion, 
whereas those contacting the y-substituents exhibited exchange dynamics, indicating two 
dynamically distinct portions o f the binding pocket. Also, two residues in transdomain 
linkers between lobes 1 and 2 show exchange, providing new insight into the previously 
proposed domain closure hypothesis. In addition, the concerted motion o f helix F 
suggests a pathway for ligand dissociation (ligand exit from the binding site) without the 
necessity o f domain reopening. Such details about intradomain motions were not 
obtained from the X-ray structures o f the S1S2 domain crystallized with ligands.
1.7.4 Photoaffinity labeling:
Photocovalent modification o f a protein can provide valuable information about 
the location and architecture o f the ligand-binding site. In photoaffinity experiments, use
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o f a purified protein preparation is very helpful, since it decreases nonspecific 
background labeling. After a labeled protein has been detected, competitors are co­
incubated with the photoaffinity label and the target protein to establish if  the labeling is 
selective. Specifically labeled proteins are those that are competitively displaced by a 100 
to 1000-fold excess o f  the unlabelled probe. Specifically labeled proteins are isolated and 
subjected to limited proteolytic digestion or chemically induced cleavage at specific 
residues. The most radioactive fragments are localized by electrophoretic or HPLC 
separation, and the size and composition can be analysed by matrix-assisted laser- 
desorption and ionization, coupled with time-of-flight (M A LD I-TO F) mass spectroscopy 
or by Edman degradation.
Photoaffinity labeling has been used to identify several important residues in the 
Torpedo ray nAChR. For example, a choline analog, [ 3H]4-Benzoylbenzoylcholine 
(Bz(2)choline) was synthesized as a photoaffmity probe for the Torpedo ray nicotinic 
acetylcholine receptor (nAChR). Photoaffmity labeling and N-terminal sequence analysis 
identified the residues у L I09 and 5 LI 11 as the primary, specific sites o f  Bz(2)choline 
photoincorporation (W ang et al., 2000). Using the photoaffmity reagent, DDF 
[p(Dimethylamino)benzenediazonium fluoroborate], residues W 149, Y190, С 192, С 193 
were labeled in an agonist-protective m anner (Dennis et al., 1988).
1.7.5 Chemical modification studies:
This m ethod is based on the use o f group-specific m odifying agents. Chemicals 
that selective m odify specific amino acids are employed in this technique. By doing 
protection experiments, one can also determine if  the residue being modified resides is
near the substrate-binding regions. In some instances, one can use irreversible, group- 
specific, chemical modifiers to react with the protein, followed by protease digestion and 
peptide sequencing to identify the location o f the residue(s) being targeted (similar to the 
method described for photoaffinity labeling studies).
Miquel et al. employed chemical modification techniques in a study involving 
purified 5-HT3Rs from NG108-15 cell membranes (Miquel et al., 1991). Among others, 
these reagents included NBS (N-Bromosuccinimide): selective for Tryptophan; DTT 
(dithioethreitol): selective for Cysteine and EEDQ (N -ethoxycarbonyl-2-ethoxy-l,2- 
dihydroquinolone): selective for Aspartate. The effects o f these protein modifying 
reagents on specific binding o f [JH] zacopride binding to 5-HTjRs were evaluated. 
Agents such as EEDQ, which alkylate carboxyl groups did not affect specific binding to 
zacopride, suggesting that carboxyl group containing residues such as aspartate and 
glutamate do not participate in recognition o f zacopride by 5 -HT3R. On the other hand, 
NBS significantly inhibited the specific binding o f  zacopride, suggesting that tryptophan 
residues participate in an interaction with this antagonist.
1.8: The approach of mutagenesis for protein structure elucidation:
Many o f the techniques described above are not suitable for structure elucidation 
o f 5"HT3R since they require high levels o f purified protein. Approaches such as 
chemical m odification studies have been used to study 5-HT3R binding site, however, 
these data require confirmation using other methods such as site-directed mutagenesis. 
Mutagenesis studies also require extensive binding and functional assays for data 
interpretation. M utagenesis has proven to be a valuable tool for structure/function studies
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in proteins. A systematic, scanning approach is also employed in some instances, where 
an area o f interest in a protein is selected and is sequentially mutated to an amino acid 
such as alanine or cysteine. This approach is also called “scanning mutagenesis” . 
Different types o f  scanning mutagenesis are discussed below.
1.8.1. ASM: Alanine Scanning M utagenesis.
This technique was first reported by Cunningham et al. who performed ASM on 
the human growth hormone (hGh) receptor to map receptor interactions (Cunningham 
and Wells, 1989). Subsequently, ASM has been utilized to study a myriad o f proteins 
including human prolactin (Goffin et al., 1992), insulin-like growth factor-1 (IGF-I) 
receptor (W hittaker et al., 2001), interleukin 4 (IL-4) receptor (Morrison and Leder,
1992), Na,K-ATPase (Arguello et al., 1999), ATP-Gated Р2Хг receptor (Koshimizu et 
al., 1998; Li ct al., 2004), calcium channels (Kraus et al., 1998; Peterson et al., 1997; 
Tedford et al., 2004), Potassium channels (Collins et al., 1997; Harris et al., 2003; Репу 
et al., 2004; Swartz and MacKinnon, 1997), sodium channels (M aejima et al., 2002; 
McPhee et al., 1994; McPhee et al., 1995; Yarov-Yarovoy et al., 2002), muscarinic 
acetylcholine receptors (Lee et al., 1996; Lu and Hulme, 1999; Lu et al., 2001; Ward et 
al., 1999).
Relatively few ASM studies have been reported so far in the field o f ligand-gated 
ion channels. An ASM study o f extracellular loop between the second and third 
transmembrane domains (TM 2-TM 3) o f the GABA a receptor has been reported (O'Shea 
and Harrison, 2000). Two ASM studies have been reported for the glycine receptor, one 
involving the signature Cys-loop (Schofield et al., 2004) and the other involving residues
in the M1-M2 loop and the M2-M3 loop (Lynch et al., 1997). In case o f  the nAChR, 
ASM has been employed to explore the contribution o f a  TM4 amino acid residues of 
mouse AChR to channel gating (Bouzat et al., 1998). In 5-HT3R, ASM has been 
employed to study D and E binding loops (Yan et al., 1999, Venkataraman et al., 2002). 
A major aim o f this thesis involved the characterization o f  binding loop С o f the murine 
5-HT3R by ASM.
1.8.1.1 Principle o f ASM:
In ASM, each amino acid o f a chosen region o f the protein is sequentially mutated 
to alanine. Each alanine mutant is characterized and the results are compared with those 
obtained for WT (wild-type) receptor. Alanine is a good candidate for amino acid 
replacement for the following reasons:
(a) It does not have any side chain beyond the P-carbon,
(b) It does not alter the main chain conformation, like a glycine and proline 
substitution,
(c) It does not impose strong steric and electrostatic effects, and
(d) Alanine is the most abundant amino acid in nature and can be found in buried 
or exposed positions, and in all secondary structures.
1.8.1.2 Data interpretation using ASM:
The effects o f  individual alanine mutations can be used as a basis for postulating 
the role o f side chain o f the mutated amino acid in receptor function, assuming no 
changes in backbone structure or global conformation have occurred because o f the 
alanine substitution. Since alanine residues are naturally found in both buried and
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exposed parts o f  proteins, alanine substitutions are very well accommodated by a protein. 
An alanine substitution o f a residue that is critical to ligand interactions, receptor 
structure and/or mechanism will lead to significant changes in expression, binding and/or 
function.
ASM provides an initial map o f  a potentially important region, especially for a 
protein about which very little structural information is available. For the 5-НТз receptor, 
very few residues in the ligand-binding site were known before ASM studies were carried 
out on B, D, С and E loop regions o f the binding site. After identification o f potentially 
key residues from the initial alanine scan, these residues can be further studied using 
other mutations. Approaches such as use o f partial agonists to decipher role o f mutated 
residue in gating, molecular modeling based on the homologous AChBP and 
immunofluorescence assays to study cellular localization o f the mutant receptor can also 
be employed to clarify the importance o f a specific amino acid. ASM can also sometimes 
be used to map secondary structure. After the entire region o f interest has been evaluated 
by ASM, if every second residue shows a large change compared to WT, then the 
secondary structure is interpreted as P-sheet. If  every third o f fourth residue shows a large 
change, the data would better support an a-helix.
1.8.2 SCAM: Substituted cysteine accessibility method:
The substituted cysteine accessibility method (SCAM) was initially used to study 
the secondary structure o f  pore-lining domains o f ion channels (Akabas, 1998; Akabas et 
al., 1992). In this method, cysteine residues are sequentially introduced into the protein 
domain o f interest. Cysteine reactivity is then assayed by exposure to highly soluble,
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sulfhydryl-specific reagents, such as methanethiosulfonate (MTS) derivatives (Karlin and 
Akabas, 1998). I f  a functional property o f the channel is irreversibly modified upon 
exposure to such a reagent, it is assumed that that the cysteine is exposed to the water- 
accessible protein surface. If  every second residue is reactive, then the secondary 
structure is interpreted as P-sheet(Akabas et al., 1992). I f  every third or fourth residue is 
exposed, the structure is interpreted as a-helical (Akabas et al., 1994). Later studies have 
also employed SCAM to study the structure o f  extracellular domains o f ion channels 
(Lynch et al., 2001; W agner and Czajkowski, 2001). However, a disadvantage of 
applying this approach outside the pore regions is that a lack o f functional modification 
o f a residue does not necessarily indicate that the residue has not reacted, i.e., negative 
results cannot be interpreted. However, this limitation is less likely to affect SCAM 
studies looking at channel pore regions, wherein the environment is spatially restricted 
and the attachm ent o f  a large side chain usually alters channel kinetics. Thus SCAM 
studies o f pore regions tend to more accurately reflect cysteine reactivity. The other 
limitation o f  SCAM is that the Cysteine substitution can itself alter function significantly 
in comparison to the W T receptor.
Two separate SCAM studies on the murine 5-HT3AR have concluded that the М2 
region o f the channel is a-helical in structure, although conclusions about the exact 
location o f the gate in the М2 region were different in each study (Panicker et al., 2002; 
Reeves et al., 2001). Various extensions to this technique have also been employed. For 
example, by determining changes in cysteine reactivity in various functional states (such
as closed, open, and desensitized), it may be possible to draw conclusions about state- 
dependent structural changes (Pascual and Karlin, 1998).
1.8.3 W SM : Tryptophan scanning mutagenesis:
This approach involves sequentially introducing tryptophan residues one at a time 
into the domain o f interest. Because tryptophan side chains are bulky, it is assumed that if 
they protrude into the relatively fluid lipid bilayer they should be less likely to disrupt 
receptor structure and function than if  they protrude towards the protein interior (Choe et 
al., 1995). Functional parameters such as agonist EC50 are m easured for each mutant 
receptor, and then a correlation is drawn between the position o f the introduced 
tryptophan and the severity o f the functional change seen as compared to WT receptor. 
As with SCAM, any resulting periodicity is interpreted as p-sheet or a-helix.
1.1.1 Sodium channel
P.
1.1.2 Calcium channel
1.1.3 Potassium channel
Subunit I
a
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1.1.4 Inward rectifier potassium channel
1.1.5 5 -Н Т з receptor: M ember of the extracellular ligand -gated ion channel family
J. -
,A
. - . - ' " И
Subunit interface
1.1.6 Pore formation and symmetry in ion channels
Voltage-gated Ligand-gated Gap junction
Figure 1.1 Ion channels: This Figure illustrates the membrane topology and arrangement 
o f different classes o f  ion channels.
Figure 1.1.1 Sodium ch an n el: This figure shows the topology o f a sodium channel 
Figure 1.1.2 Calcium channel: This figure shows the topology o f a calcium channel.
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Figure 1.1.3 Potassium channel: This figure illustrates a single subunit o f a potassium 
channel;
Figure 1.1.4 Inward rectifier potassium channel: This figure illustrates an inward 
rectifier potassium channel.
Figure 1.1.5 5-HTj receptor: Member of the extracellular ligand -gated ion channel 
family: This figure shows the topology o f a single subunit o f  a 5 -HT3R, which belongs to 
the Cys-loop ligand gated ion channel family.
Figure 1.1.6 Pore formation and symmetry in ion channels: This figure compares the 
pore formation and symmetry in voltage-gated, ligand-gated and gap junction ion 
channels.
serotonin 2-m ethyl-5-H T 5-I1TQ
PSAB-OFP
te trahydro th iazo lopyridm es
Figure 1.2 Chemical structures of 5-HT3R agonists
This figure shows the chemical structures o f different classes o f 5-HT3R agonists.
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Figure 1.3 Sum m ary of the revised 5-HT3R antagonist pharm acophore originally 
developed by H ibert et al..
Summary o f 5 -HT3R antagonist pharmacophore model put forth by various research 
g roups.a Results put forth by Hibert et al. Results put forth by Swain et a l c Results put 
forth by Rizzi et al.
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tropisetron
(indoles)
H .C - N
granisetron
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CH,
ondansetron
(carbazolcs)
(+)tubocurarine
MDL 72222 
(benzoates)
zacopride
(benzamides)
Figure 1.4 Chem ical structures of some 5-HT3R antagonists:
This figure shows the chemical structures o f different classes o f 5 -HT3R antagonists.
lerisetron
Figure 1.5 Chem ical structure of lerisetron
This figure shows the chemical structure o f lerisetron, a novel benzimidazole 
containing 5 -HT3R antagonist.
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Figure 1.6 Suggested mechanism of activation o f muscle nAChR
The mechanism o f  activation o f  muscle nAChR proposed by Unwin et al (2002), based 
on comparison o f  open and closed state structures o f the receptor at 4.6A.
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Chapter 2: Specific aims and experimental rationale
Before work was started on this project, very few residues in the putative 5 -HT3R 
ligand-binding site had been characterized. A relatively preliminary picture o f the binding 
site was available. It was known that residues W89 and R91 (loop D), W183 (loop B), 
E l26 and F I 27 (Loop A) contribute to the binding site. Our laboratory reported three 
important tyrosines Y141, Y143 and Y153 in the Loop E region o f  the binding site 
(Venkatarman et al., 2002). The AChBP had just recently been discovered and no 
homology models o f any LGIC receptor were available. We constructed a preliminary 
homology model o f  the murine 5-HT3aR based on the AChBP. Based on this model and 
previous biochemical studies, it was evident that the +face o f  the binding site is formed 
loops A-С and the -face is formed by loops D-F. The model also indicated that Loop С 
spans across the subunit interface and also implied that this loop plays an important role 
in forming the binding site. Such a role is also supported from previous reports from 
Loop С residues (Y190, С 192, С 193 and Y198) o f the nAChR. Regarding agonist action, 
it was unknown if  any region(s) o f the binding site specifically modulate the action o f 
any agonist, i.e. the m olecular determinants for binding o f one agonist vs. the other were 
unknown. The second 5-HT3R subunit, i.e. the 5-НТзВ subunit was reported in 1999 and 
its contribution (if any) to the 5-HT3AbRbinding site was unknown (Davies et al., 2002).
In order to develop a refined picture o f the 5-HTiR binding site and understand 
the role o f the В subunit in 5-HT3R structure and function, we followed a multifaceted 
approach. This approach involved alanine scanning mutagenesis, molecular modeling,
evaluation o f chimeric receptors and SAR (structure activity relationship) studies of 
lerisetron. The specific aims that employed these approaches are explained below.
2.1 Specific aims of this study:
2.1.1 Aim 1: ASM study and detailed characterization of Loop С region of the 5- 
H T 3R binding site:
The aim o f  this study was to conduct an alanine scanning mutagenesis (ASM) of 
the Loop С region o f the murine 5-HT3R, followed by a detailed characterization o f key 
residues in this region. As discussed earlier, ASM is useful in characterization o f a region 
o f a protein about which little is known. Loop С is an ideal candidate for ASM because 
this region is highly unconserved in the LGIC family. Since ASM involves sequential 
alanine mutations o f all amino acids in the region, residues can be studied in an unbiased 
manner. All mutations are studied using saturation and competition radioligand assays, 
two-electrode voltage clamp assays, and immunofluorescence assays (as explained in 
experimental design). Once potentially key residues are identified from the initial scan, 
they can be evaluated in further detail by more detailed functional assays involving 
partial agonists. Using conservative mutations, the importance o f amino acid side chain 
characteristics in receptor function can be assessed. Results from such studies also impact 
studies o f  other LGICs due to presumed structural similarities between family members. 
In addition, work on the Loop С region provides more information about an unconserved 
domain in all LGIC receptors (see chapter 3, figure 3.1, for sequence alignment).
A secondary aim o f this study was to correlate the biochemical data obtained in 
mutagenesis studies with ligand docking calculations obtained from AChBP-based 5-
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HT3R hom ology models. The docking calculations were carried out by Dr. Zsolt Bikadi. 
Such models predict interaction o f agonists and antagonists with specific residues in the 
binding site. Such predictions can be assessed by biochemical data and can help in 
formation o f  more refined models, new hypotheses about ligand interaction and channel 
activation mechanisms. The results o f this study are discussed in Chapter 3.
2.1.2 Aim 2: Structure activity relationship (SAR) study of lerisetron, a 5-HT3R 
antagonist:
The objective o f  this study was to investigate the importance o fN l  substituents o f 
lerisetron, a novel 5 -HT3R antagonist (see chapter 4, Fig 4.1). Lerisetron is a novel 5- 
HT3R antagonist benzimadole ring (Orjales et al., 1997), which is currently in Phase III 
o f clinical trials for treatment o f chemotherapy-induced emesis (Huckle, 2003). The 
chemical nature (electrostatic, hydrophobic interaction etc) o f  N1 substituents that is 
required for optimal biological activity is unclear. To understand the importance o f the 
N1 substitution, nine N 1-substituted lerisetron analogs were synthesized by Dr. Karen 
Kirschbaum ’s laboratory. These analogs were evaluated for their biological activity 
employing two-electrode voltage clamp assays in oocytes expressing human 5-НТзА 
receptors. Results o f  this study are discussed in chapter 4.
2.1.3 Aim 3: Investigation of role of В subunit employing A-В chimeric receptors:
As discussed earlier, the role o f N-terminal o f the В subunit in heteromeric AB 
receptor function is not known. It is known that the В subunit confers different 
biophysical and pharmacological properties to the AB receptors. To determine if  there 
were any molecular determinants o f structure and/or function in the aminoterminal o f the
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В subunit, we designed a pilot study involving chimeric constructs o f A and В subunits. 
The results o f  this study are discussed in Chapter 5.
2.2 Experimental rationale:
When point mutant or chimeric receptors are employed in radioligand binding and 
functional studies, there is a concern that the changes seen are merely due to structural 
alterations. In addition, it is also not easy to dissect if  an amino acid plays a role in ligand 
binding, gating or assembly. In order to clearly identify the putative role played by each 
amino acid or a region o f the 5-HTiR, we have employed a combination o f different 
assays. The rationale behind choosing each assay, inherent advantages and disadvantages 
are explained below.
2.2.1 Radioligand binding assays:
Radioligand binding assays offer a quick (relative to patch-clamp or two-electrode 
voltage clamp assays) evaluation o f an entire region o f a protein such as the binding loop 
С o f the 5 -HT3R. We have carried out both saturation and competition assays in our 
studies.
2.2.1.1 Saturation binding assays employing [JHJ granisetron:
A tritiated form o f granisetron, BRL-43694 was employed in saturation 
binding assays. [ H] granisetron was chosen since it is a highly specific and potent 
competitive antagonist o f the 5 -HT3R. M embrane preparations o f  mutant receptors 
expressed in mammalian USA  201) cells were employed in binding assays to determine 
K<j (affinity) and BMax values. BMax values o f mutant receptors are compared with that of 
WT receptors. BMax values provide a numerical estimate o f mutant receptor expression in
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mammalian cells. I f  the IQ value o f a mutant receptor is not significantly different from 
the WT receptor, it suggests that the alanine mutation has not caused any global structural 
changes in the protein. However, if  large changes in Kd value are seen, it is not easy to 
distinguish if  the binding detected indicates binding to cell-surface receptors or 
intracellularly located receptors/receptor subunits. Some mutant or chimeric receptors can 
be intracellularly retained and can still show binding to [ FI] granisetron. In such cases, an 
epitope tag can be added to the mutant/chimeric receptor to determine cellular 
localization by fluorescence microscopy.
2.2.1.2 Competition assays:
Competition assays are performed with agonists such as 5-HT and wCPBG in the 
presence o f  [ H] granisetron. Such assays provide a quick initial estimate o f any 
significant changes in affinity o f the agonist for the mutated receptor compared to WT 
receptor. Typically, the mutants that show large changes in affinity in competition assays 
also produce changes in electrophysiological assays. Although these changes are usually 
not quantitatively similar in radioligand and electrophysiological assays, they typically 
follow the same trend. Agonists, unlike antagonists propel the receptor population to the 
desensitized state, which is presumably the most dominant state o f  the receptor in such 
competition assays. Thus, competition assays presumably reflect the affinity o f the 
agonist for the desensitized state o f the receptor.
2.2.2 Electrophysiological assays:
Two-electrode voltage clamp assays are carried out using mutant receptors 
expressed in Xenopus laevis oocytes. This expression system is especially useful for
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characterization o f  mutant receptors that show very poor expression levels in mammalian 
expression systems. Xenopus oocytes produce large num ber o f  mutant receptors that can 
be studied relatively easily and quickly using two electrode voltage clamp assays. On the 
other hand, post-translational modifications may be different in Xenopus oocytes as 
compared to mammalian cells. Also, certain ion channels can not be studied in Xenopus 
oocytes if  the similar ion channel is also natively expressed in oocytes. These concerns 
should be borne in mind and comparison o f two-electrode voltage clamp data with 
whole-cell patch-clamp assays in mammalian cells should be carried out for the WT 
receptors.
If  application o f an agonist elicits a current from an oocyte expressing a mutant 5- 
H T 3R, it indicates cell surface expression o f  intact pentameric receptors. Biophysical 
parameters such as EC 50, Hill number (пн) and IMax (maximal current elicited upon 
application o f  agonist) can be calculated from such assays. Імах values indicate receptor 
number. A significant decrease in Імах value for all agonists indicates decreased 
expression. However, if  there is no concurrent change in Вмах value, or if the decrease in 
I Max is specific for an agonist, the mutation has selectively decreased efficacy for that 
agonist. Changes in EC 50 values for a mutant receptor can occur due to a change(s) in 
binding and/or gating steps in the receptor activation pathway. A decrease in receptor 
number alone does not change the EC50 value. A role in gating can be studied employing 
the partial agonist approach (described in Chapter 3).
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2.2.3 M olecular modeling:
The discovery o f the AChBP in the snail Lymnaea stagnalis has accelerated LGIC 
studies by m aking possible homology based receptor modeling. Homology models o f 5- 
HT3R enable improved interpretation o f biochemical data from mutagenesis studies. 5- 
HT?R ligands can be computationally docked into such hom ology model. Such docking 
calculations for multiple ligands can be correlated with biochemical experiments. The 
docking calculations and biochemical experiments are independently performed without 
influencing each other. Corroboration o f biochemical data with the information obtained 
from docking calculations can also provide information about protein 
dynamics/movements o f the protein between various conformational states. Based on the 
biochemical data, the homology model can be further refined and newer models o f the 
receptor can be constructed.
I f  ligand docked models predict that a residue is not within 4Л o f ligand and if 
biochemical data do not support a role in binding, it can be concluded that the particular 
residue is not involved in ligand binding. Similar conclusions about gating can also be 
reached using a combination o f partial agonist data and m olecular modeling
2.2.4 Im m unofluorescence assays:
I f  a mutation fails to produce detectable binding to radioligand and/or 
electrophysiological responses to agonists, the cellular localization o f  the receptor can be 
determined employing immunofluorescent detection o f  epitope tagged receptors. For 
such experiments, FLAG or GFP tagged WT and mutant/chimeric receptors were 
constructed. To rule out any effects due to insertion o f  an epitope tag, tagged WT
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receptors were evaluated using both radioligand binding and electrophysiological assays. 
In immunofluorescence assays o f tagged mutant receptors, if cell surface expression is 
abolished, it can be concluded that the mutation causes changes in receptor assembly 
and/or trafficking. On the other hand, if cell surface expression is unaltered, then the 
changes observed for the mutation are due to ligand binding and/or gating.
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Chapter 3: Characterization of residues in the loop С region of the 
murine 5-HT3aR by site-directed mutagenesis.
3.1 Abstract
Sequence and predicted structural similarities between members o f the Cys-loop family 
o f ligand-gated ion channel receptors and the acetylcholine binding protein (AChBP) 
suggest that the ligand-binding site is formed by six loops that intersect at subunit 
interfaces. We investigated the role o f amino acids o f the loop С o f the murine 5-HTjasR 
by site-directed mutagenesis. Mutant receptors were evaluated using radioligand binding, 
two-electrode voltage clamp and immunofluorescence studies. Two structurally distinct 
agonists, 5-HT and mCPBG; as well as the antagonist granisetron were evaluated on 
mutant receptors. In addition, electrophysiological studies comparing efficacies o f 
agonists and partial agonists were carried out to elucidate the role o f  key amino acids in 
the receptor gating mechanism. Our results indicate that 5-HT and wCPBG interact 
differentially with the Loop С region. To further corroborate our observations, we carried 
out ligand docking calculations for 5-HT and mCPBG using an AChBP-based 5 -HT3R 
homology model. The combined results indicate that D229 is an important difference in 
the binding modes o f  5-HT and mCPBG. While D229 is critical for binding o f  5-HT and 
not mCPBG, mutation o f 1228 differentially modulates gating by 5-HT and not wCPBG. 
In addition, residues E225, F226 and Y234 from loop С are involved in mediating actions 
o f both 5-HT and mCPBG.
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3.2 Introduction
The serotonin type 3 receptor (5 -HT3R) is a member o f the Cys-loop superfamily 
o f ligand-gated ion channel (LGIC) receptors that includes nicotinic acetylcholine, 
GABAa, GABAc and glycine receptors (Maricq et al., 1991). These receptors are 
membrane-bound ion channel coupled receptors that mediate fast synaptic transmission 
in both peripheral and central nervous systems. 5-НТзд subunits form homopentamers 
that yield characteristic inward currents with rapid onset and desensitization on exposure 
to agonist. The ligand-binding site is present in the extracellular amino terminal domain, 
at the subunit interface. 5 -HT3AR antagonists are clinically used for the treatment o f 
chemotherapy-induced emesis, and are being evaluated for several other conditions 
including alcoholism (Costall and Naylor, 2004)
Sequence and predicted structural similarities between LGIC receptors and the 
acetylcholine binding protein (AChBP) suggest that the ligand-binding site is formed 
from six loops, A-F, which intersect at the subunit interfaces (Arias, 2000; Brejc et al., 
2001; Le Novere et al., 2002; Reeves et al., 2003). Several important residues in the 5- 
HT3R binding domain have been identified: E129, F I 30 (loop A), W183 (loop В), E225, 
Y234 and E236 (loop C), and W90 and R92 (loop D) (Boess et al., 1997; Price and 
Lummis, 2004; Schreiter et al., 2003; Spier and Lummis, 2000; Steward et al., 2000; Yan 
et al., 1999). Earlier work from our laboratory identified three important tyrosine residues 
(Y 141, Y143 and Y153) in the loop E region o f the 5 -HT3R (Venkataraman et al., 2002). 
The development o f  AChBP-based homology models o f  the 5 -HT3R binding domain
have also greatly increased our understanding o f binding interactions o f agonists and 
antagonists (Brejc et al., 2001; M aksay et al., 2003; Reeves et al., 2003).
Previously, residues in the loop С region have been shown to contribute to the 
higher potency o f d-TC  at the mouse 5-HTiR as compared to human receptors (Hope et 
al., 1999). This region has also been shown to contribute to the selective potency o f 1- 
phenylbiguanide at human 5-HTiRs (Lankiewicz et at., 1998). Similarly, the loop С 
region has also been implicated in the higher potency o f mCPBG at rat 5 -HT3RS 
(Mochizuki et al., 1 9 9 9 ) . 5-HT and wCPBG have been shown to exhibit distinct profiles 
on the murine 5-HT3AR. mCPBG shows higher apparent affinity, slower association rates 
and higher affinity for the desensitized state compared to 5-HT (Bartrup and Newberry, 
1996; Mott et al., 2001; van Hooft and Vijverberg, 1997). The molecular basis o f these 
differences is not known. Recently, residues E225, Y234 and E236 from the loop С 
region o f the mouse 5 -HT3R have been postulated to play a role in the ligand binding 
and/or gating (Price and Lummis, 2004; Schreiter et al., 2003). However, the assignment 
o f a role in gating for the aforesaid residues is speculative since it is based only on 
changes in EC50 and/or K, values (Colquhoun, 1998). A comparison o f unliganded and 
liganded crystal structures of AChBP suggests that the loop С region undergoes the 
largest movement after agonist binding (Celie et al., 2004). A substituted cysteine 
accessibility m ethod (SCAM) study o f the loop С region o f the (З2 GABAaR also 
implicates this region in conformational changes after agonist binding (W agner and 
Czajkowski, 2001). The loop С region in the 5 -HT3R is likely to play a similar role.
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However, a detailed evaluation o f the role o f each loop С residue in ligand binding and 
gating remains unavailable.
In this study, we carried out a comprehensive analysis o f the putative loop С 
region in the murine 5-HT3AR by sequentially mutating each residue in this region. All 
mutants were characterized by radioligand binding and electrophysiological assays. 
Immunofluorescence assays were carried for mutants that ablated binding and/or 
function. We also employed electrophysiological studies comparing efficacies o f 5-HT, 
wCPBG and the partial agonist 2-methyl 5-HT (2-M e 5-HT) to demarcate the role o f the 
mutated residue in gating o f the receptor. Residues E225, F226, D228, 1229 and Y234 
were identified as critical for ligand interaction. Our experimental results support 
differences in modes o f interaction o f 5-HT and mCPBG with the loop С region. To 
further investigate these differential interactions, we employed docking studies using a 5- 
HT3R homology model based on the AChBP. The experimental results are in good 
agreement with the ligand docking calculations. The combined results show that D229 is 
a major point o f difference in the modes o f interactions o f 5-HT and mCPBG with the 
murine 5 -HT3AR. Our results also support a role o f residues E225, F226 and Y234 in 
gating o f the receptor. On the other hand, mutation o f 1228 selectively alters gating by 5- 
HT and not mCPBG. S233 and Y234 are also critical for receptor assembly and/or 
trafficking. In combination, the experimental and modeling data reveal an emerging 
picture o f distinct interactions o f 5-HT and mCPBG with the Loop С region o f the 5-
h t 3Ar .
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3.3 M aterials and Methods:
[H ]  granisetron was purchased from New England Nuclear (NEN, MA, US). 5- 
HT and 2-Me 5-HT were obtained from Spectrum and mCPBG was obtained from 
Research Biochemical International (MO, US) . Xenopus laevis frogs and frog food were 
obtained from Xenopus Express (FL, US). Sigma Type II collagenase was purchased 
from Sigma Aldrich (MO, US). All other chemicals were purchased from Fisher 
Scientific (TX, US).
3.3.1 Site-directed mutagenesis and epitope tagging:
Site directed mutagenesis was performed as described earlier (Venkataraman et 
al., 2002), using either the QuickChange mutagenesis kit, (Stratagene, CA, US) or the 
pAlter altered sites mutagenesis kit (Promega, WI, US). In order to add a C-terminal 
FLAG epitope tag, the WT cDNA was cloned into the pCM V 4.1 vector (Stratagene, CA, 
US). This W T-FLAG cDNA was then used as a template to create the FLAG-tagged 
F226A, S233A and Y234A mutations using the Q uickChange1' mutagenesis kit. All 
constructs were confirmed by restriction digests and DNA sequencing (UC Davis, CA,
3.3.2 Cell culture and transient transfection:
/SA 201 cells (a derivative o f HEK 293 cells) were cultured in Dulbecco’s 
modified Eagle medium (DMEM, New Life Technologies, NY, US) supplemented with 
10% fetal bovine serum and 100 units/ml penicillin/streptomycin in a humidified 5% C 0 2 
atmosphere at 37°C. For radioligand binding studies, ?SA201 cells were plated on 90mm 
culture dishes at a density o f  5 x 106 cells/dish and grown for 9 hours prior to transfection.
The cells were transfected with 20j_tg/ dish WT or mutant plasmid DNA using a calcium 
phosphate transfection kit (New life technologies, NY, US). Transfected cells were 
supplemented with fresh DMEM 12-15 hours after transfection and harvested 36 hours 
later.
3.3.3 Radioligand binding assays:
These assays were performed as described earlier (Venkataraman et al., 2002). 
Briefly, transfected cells were scraped from the dishes, washed twice with PBS (New 
Life Technologies, NY, US), then resuspended in 1.0 ml PBS with protease inhibitor 
cocktail /100mm dish (Complete protease inhibitor cocktail, Roche, Mannheim, 
Germany). Immediately prior to use, cells were homogenized in PBS with protease 
inhibitors using a glass tissue homogenizer, centrifuged, washed and resuspended in 1ml 
PBS/100 mm dish. Protein content was determined using Lowry assay (Sigma 
Diagnostics, MO, US). Binding assays were performed in PBS with protease inhibitors. 
For determinations, 50ц1 o f homogenate was incubated at 37°C for 1 hour with 
varying concentrations o f [JH] granisetron. Specific binding o f  [ H] granisetron was 
determined as the bound [ H] granisetron not displaced by a saturating concentration o f a 
competing ligand (Ю цМ  tropisetron). For K, determinations, 50jxl o f  homogenate was 
incubated at 37°C for 2 hours with varying concentrations o f  inhibitor and [ H] 
granisetron (NEN, MA). Binding was terminated by rapid filtration onto a GF В filters.
3.3.4 Electrophysiology:
Details o f  the chamber and methodology employed for electrophysiological 
recordings have been described earlier (Joshi et al., 2004). Briefly, ovarian lobes were
surgically removed from Xenopus laevis frogs and washed twice in Ca 2 free Barth’s 
buffer [82.5mM NaCl / 2.5mM KC1 / ImM M gCh / 5mM HEPES, pH 7.4] and gently 
shaken with 1.5mg/ml collagenase (Sigma type II, Sigma-Aldrich) for 1 hour at 20-25°C. 
Stage IV oocytes were selected for microinjection. Synthetic cRNAs for WT and mutant 
mouse 5-HT3as were prepared using the mM ESSAGE mM ACHINE™  High Yield 
Capped RNA Transcription Kit (Ambion, TX, US). Each oocyte was injected with 50 nl 
cRNA at a concentration o f 0.2ng/nl. Oocytes were incubated at 19°C for 2 to 4 days 
before electrophysiological recording. Electrical recordings were made under 
conventional two-electrode voltage-clamp using an OC-725C oocyte clamp amplifier 
(W arner Instruments, CT, US) coupled to an online, computerized data acquisition 
system (Datapac 2000, RUN technologies, CA, US). Recording and current electrodes 
were filled with ЗМ КС! and had resistances o f 1-2 mH. Oocytes were held in a vertical 
flow chamber o f 400 ці volume and perfused with ND-96 recording buffer (96mM NaCl 
/ 2mM KC1 /1.8mM  CaC h i  ImM M gCh / 5mM HEPES, pH 7.4) at a rate o f  15ml/mm. 
All agonists were prepared in ND-96 buffer and applied at a rate o f 25ml/min using an 
electrical pump.
3.3.5 Com parison of relative efficacy values of agonists on WT and mutant 
receptors:
Maximal currents elicited by each agonist were recorded using saturating 
(supramaximal) concentrations o f the agonist. 5-HT was assumed to be the full agonist 
based on data obtained for WT receptor. Relative efficacy o f an agonist (relative to 5-HT) 
was calculated as Імах Agonist/ Іма* 5-H T. For each experiment, m aximal currents elicited by
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mCPBG and 2-Me 5-HT were compared (normalized) to the maximal current elicited by 
5-HT on the same oocyte. Such comparisons were repeated on four or more oocytes for 
WT and mutant receptors. All the normalized data were pooled together to calculate 
relative efficacy values ±  S.E.
3.3.6 Receptor modeling:
Extracellular regions o f the homopentameric murine 5-HT^R were built based on 
the crystal structure o f AChBP from the snail Lymnaea stagnalis (PDB entry: 1I9B). The 
sequence o f 5-HT3R A subunit was taken from the Protein Information Resource (Wu et 
al., 2002) with an entry code o f NF00508262. M ultiple sequence alignments o f their 
extracellular regions and AChBP were performed by ‘ClustalW ’ using default parameters 
(Thompson et al., 1994). Based on this alignment, homology-model building o f 5-HT3aR 
subunit was carried out using the ‘N est’ and ‘Loopy’ facility o f the Jackal protein 
structure m odeling package. ‘N est’ predicts the experimental dihedral angles chil within 
an error range o f 20 degrees for 94% o f protein side chains (Xiang and Honig, 2001). 
Protein loop predictions for amino acid insertions and deletion were done by 
‘Loopy’(Xiang et al., 2002). Heterodimeric units o f  the pentam er were built on the basis 
o f crystal structure data to reach minimal root mean standard deviation (RM SD) between 
the matched monomers. Further refinements o f the resulting dimers were carried out by 
Sybyl 6.6 program (Tripos Inc., MO, US) on a Silicon Graphics Octane workstation 
under Irix 6.5 operation system. The all-atom model was allowed to relax during a short 
molecular dynamics run using constraints for backbone atoms. Finally, the entire 
structures were fully minimized without any restriction using Powell conjugate gradient
method until the maximum derivative was less than 0.050kcal/molA. Gasteiger-Huckel 
partial charges were applied during the calculations. The quality o f the model was 
verified using ‘Procheck’, as compared with well-refined structures at the same resolution 
(Laskowski et al., 1993). Intra- and interface H-bonds were analysed by HBPLUS v 3.0, 
an hydrogen bond calculation program (McDonald and Thornton, 1994).
3.3.7 Ligand docking:
Ligand docking was performed independent o f the experimental data, i.e., no 
constraints based on the experimental data were applied. ‘AutoDock 3 .0’ (Morris et al., 
1998) was applied for docking calculations, using the Lamarckian genetic algorithm 
(LGA) and the ‘pseudo-Solis and W ets’ (pSW) methods. The parameters included in 
Autodock are based on the ‘Assisted Model Building with Energy Refinem ent’ 
(AMBER) force field (Cornell et al,, 1995). Gasteiger-Huckel partial charges were 
applied both for ligands and proteins. Solvation parameters were added to the protein 
coordinate file and the ligand torsions were defined using the ‘A ddsol’ and ‘Autotors’ 
utilities, respectively, in Autodock 3.0, The atomic affinity grids were prepared with 
0.375A spacing using the Autogrid program for a 15 x 15 x 22.5A box around the 
interface o f subunits. Random starting positions, orientations and torsions (for flexible 
bonds) were used for the ligands. Each docking run consisted o f 100 cycles. The number 
o f evaluations was set to 1.5 million. Final structures with RMSD less than 1.5A were 
considered to belong to the same cluster. The structures with low energies and high 
frequencies o f  docking were subjected to a further minimization by Sybyl and were 
examined.
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3.3.8 Localization of W T and mutant 5-H T3Rs by immunofluorescence:
W T-FLAG (W T 5-НТза R with a C-terminal FLAG tag), F226A-FLAG, S233A- 
FLAG and Y234A-FLAG were characterized by immunofluorescence in tSA  201 cells. 
(SA  201 cells transiently expressing either the WT or mutant 5-HTiRs were grown in 
chamber slides in DMEM at 37° C. 24-28 hours post transfection, chamber slides were 
washed thrice with PBS and incubated in freshly prepared ice-cold 4% paraformaldehyde 
in PBS in order to fix the cells. The chamber slides were then incubated with an anti­
FLAG antibody (Sigma, MO, LIS) at a dilution o f 1:200 in PBS for 1 hour at room 
temperature. In order to determine intracellular expression, cells were permeabilized by 
incubation with primary anti-FLAG antibody diluted in 0.3% Triton X-100. After three 
PBS washes o f  5 m inutes each, slides were incubated for 1 hour at room temperature with 
goat anti-mouse Rhodamine-conjugated secondary antibody (Jackson ImmunoResearch, 
PA, US) diluted at 1:1000 in PBS. After three PBS washes, slides were mounted and 
observed under a Nikon upright microscope with appropriate filters. The cells were 
viewed under 20 X power and photographed using a Cool Snap digital camera attached to 
the microscope. Polymorph software was used to acquire digital photographs.
3.3.9 Data Analysis:
Radioligand binding data were analyzed as follows: Kj values were determined 
by fitting the binding data to the following equation using GraphPad PRISM (San Diego, 
CA, US): В = (Bmax [L]n) / ([L]" + Kn), where В is specifically bound ligand, Bmax is the 
maximum binding at equilibrium, L is the free ligand concentration, К is the equilibrium 
dissociation constant and n is the Hill coefficient.
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IC50 values were calculated by fitting the data to the following equation using 
GraphPad PRISM (San Diego, CA, US): 0 = 1 /  (1 +(L/IC 5o)), where Ѳ is the fractional
amount o f [ H] granisetron bound in the presence o f inhibitor at concentration L as
\ • . . . .  
compared to the amount o f [ H] granisetron bound in the absence o f inhibitor. IC50 is the
concentration at which Ѳ =  0.5. Kj values were calculated from IC 50 values using the
Cheng-Prusoff equation.
Dose response curves obtained from electrophysiological data were fit using this
equation: 1= Im (1+ E C 5o/[A]n), where I is the current at a given agonist concentration,
Імах is the maximal current, EC50 is the agonist concentration that elicits half-maximal
current, and n is the Hill coefficient.
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3.4 Results:
3.4.1 Characterization of WT receptors:
Saturation binding assays using homogenates o f  tSA 201 cells expressing WT 
receptors showed that [ H] granisetron labeled a hom ogeneous population o f binding 
sites (Table 3.1). Competition binding assays were carried out to determine the affinity of 
agonists, 5-HT and mCPBG. The К  values o f both agonists were similar, as shown in 
Table 3.1.
In order to evaluate functional characteristics, WT receptors were expressed in 
and evaluated using two-electrode voltage clamp studies in Xenopus laevis oocytes 
(Table 3.2). EC50 and nH values obtained for the WT receptor are in close agreement with 
previously published data (Hope et al., 1993). The W T-FLAG receptors were 
functionally indistinguishable from the untagged WT receptors (Data not shown).
Kd, K h and EC50 measurements for a mutant receptor can indicate that a particular 
amino acid is potentially important. Scheme 1 shows the del Castillo and Katz 
mechanism o f receptor activation, where the agonist A binds to the receptor and forms 
the complex AR, which isomerizes to form the open channel AR*.
K A E
A  +  R <—> A R  <— > A R *
Any alteration in either ‘KA’ (equilibrium dissociation constant) or ‘E ’ 
(equilibrium gating constant) as a result o f  a mutation will produce an altered EC50 or K ; 
value for an agonist. It is difficult to distinguish if  such alterations are due to a change in
binding interaction or due to a change in signal transduction to the channel (gating) 
(Colquhoun, 1998). The partial agonist approach has been previously employed in 
G A B A a and glycme receptors to elucidate the role o f an amino acid in gating (O'Shea 
and Harrison, 2000; O'Shea et al., 2000; Rajendra et al., 1995). In this approach, maximal 
currents (Імах) o f  full and partial agonist are compared on a single receptor preparation 
for both the wild-type and mutant receptors. Імах is described by the equation IMax = 
тРОмах, where i is the single channel conductance, n is the receptor number and РОмах is 
the maximum fraction o f activated receptors. РОмах, in turn is described by the equation. 
РОмах = E /(l+ E ) (Lynch, 2004). Since the Імах values for all the agonists are being 
measured on a single preparation, the receptor number (n) is constant. Assuming that the 
single channel conductance (/) and the desensitization rates remain unchanged because of 
the mutation, the measurement o f fractional Імах ratios (relative efficacies) can be 
correlated with changes in E (Lynch, 2004).
We have employed voltage clamp assays to compare rank efficacy o f  full and 
partial agonists on WT and mutant receptors. A mutation affecting gating should result in 
an appreciable reduction in the relative efficacy o f a partial agonist in comparison to a 
full agonist. In such cases, a comparison o f relative efficacy ratios o f the partial agonist 
on WT and mutant receptors (for example, Імах г-мезнт/І мах 5-нт) can provide a very good 
indication o f  the role played by the mutated amino acid in gating. A gating role may 
indicate either alteration o f the ability o f the receptor to change conformation or the 
ability o f  the agonist to stabilize the open conformation o f the receptor. To this end, we 
determined relative efficacies o f wCPBG (IMax тсрва/ Імах s-нт) and 2-Me 5-HT (IMax 2-ме
5-нт i Імах 5-нт) fof W T receptors (Fig 3.2 and 3.4). These 1мах comparisons were carried 
out on the same oocyte, and such comparisons were repeated on several oocytes (n>4) as 
described in ‘M aterials and M ethods’. The HC50 value o f 2-Me 5-HT was 16.4 ±  І.ІцМ  
for WT. The rank efficacy observed for WT receptors was 5-HT> mCPBG »  2-Me 5- 
HT (Fig 3.2). In comparison to 5-HT, the relative efficacy o f mCPBG (IMax mCPBG / Імах 5- 
нт) was 0.93 ± 0.01, while that o f 2-Me 5-HT (IMax 2-ме 5-нт / Імах 5-нт) was 0.12 ± 0.002 
(Fig 3.4). Average I Max 5-нт and IMax тсрвс values for W T receptors were 14.8± 2.2 and 
13.7 ±  1.8pA, respectively (Table 3.2).
3.4.2 S227A, I230A, S231A and N232A receptors:
Alanine mutations o f residues S227, 1230, S231 and N232 did not differ 
significantly from WT receptors in radioligand and electrophysiological assays (Tables
3.1 and 3.2). The small shifts seen in Kd and EC50 values are not significant, considering 
the drastic alanine mutation. Thus, residues S227, 1230, S231 and N232 do not seem to 
play a significant role in ligand binding, structure and function o f the mouse 5-HT3As R
3.4.3 E225A receptors:
In radioligand binding assays, E225A receptors showed modest changes in 
affinity for granisetron, 5-HT and wCPBG as compared to W T receptors, with the largest 
fold change seen for 5-HT (Table 1). In electrophysiological assays, only small changes 
were noted in EC50 values o f 5-HT and mCPBG. Although the Вмах value o f E225A 
receptors was comparable to WT, the average Імах5-нт and Імах тсрвс were significantly 
lower for E225A receptors as compared to WT receptors. These low IMax values could
either be due to reduced expression o f the mutant receptors in oocytes, or due to impaired 
gating. To determine if  a role in gating was involved, we carried out relative efficacy 
comparisons for E225A receptors. The rank efficacy for E225A receptors was similar to 
that for W T receptors (i.e. 5-HT> mCPBG »  2-Me 5-HT). However, the efficacy o f 2- 
Me5-HT relative to 5-HT was substantially reduced (0.04 ±0.001) for E225A receptors 
with a corresponding increase in EC50 value to 28.1 ± 3.1 (xM (Fig 3.4). This decrease in 
relative efficacy o f  2-M e5-HT suggests a role o f E225 in gating.
3.4.4 F226A and F226Y receptors:
F226A receptors did not any significant change in Kj value o f granisetron as 
compared to W T receptors. However, large fold changes in Kj value o f 5-HT, with 
relatively smaller changes in K; o f mCPBG were noted (Table 3.1). No responses could 
be obtained in Xenopus  oocytes injected with F226A mRNA. Immunofluorescence 
experiments revealed that F226A receptors were expressed on the cell surface (Fig 3.6). 
These data indicate that an aromatic residue at position 226 is required for agonist 
induced channel opening o f the murine 5-HT-tAR.
F226Y receptors showed a radioligand binding profile similar to that o f F226A 
receptors (Table 3.2). A larger fold change in K, value o f 5-HT than that o f mCPBG was 
observed. In electrophysiological assays, 5-HT and mCPBG elicited responses on F226Y 
receptors were characterized by decreased Імах, slow onset and slow desensitization (Fig
3.2), with a moderate change in EC50, compared to WT (Table 3.2).
The rank efficacy for F226Y receptors changed to wCPBG > 5-HT »  2-Me5- 
HT. wCPBG elicited currents with Імах values higher than those elicited by 5-HT (Імах5-
нт = 0.5 ±  0.2цА, І м а х  w c p b g  = 0.8 ±  0.2цА). Thus the relative efficacy o f wCPBG was
1.6 ± 0.07, as compared to 0.93 ± 0.01 for WT receptors (Fig 3.4). Concentrations o f 2- 
Me 5-HT as high as 3mM yielded currents with amplitudes o f  < 0.01 цА in all oocytes 
expressing F226Y receptors. Given the low IMax values obtained for the most efficacious 
agonist (mCPBG); we could not determine an E C 50 value o f 2-Me 5-HT for the F226Y 
receptor. The changed rank efficacy and response kinetics o f F226Y receptors are 
indicative o f a role in gating for F226 residue. This role is also supported by significantly 
reduced Імах values with no concurrent reduction in BMax, although we cannot rule out the 
possibility that the low IMax values are due to reduced receptor expression in Xenopus 
oocytes (Table 3.1 and 3.2).
3.4.5 I228A receptors:
I228A receptors showed a -  4 fold increase in Kd value o f  granisetron. The K, 
value o f 5-HT selectively increased by 235 fold, with only a 5 fold change in Kj value o f 
wCPBG (Table 3.1). This selective effect for 5-HT was also reflected in the response 
kinetics for 5-HT and mCPBG (Fig 3.3). While 5-HT responses were markedly altered 
for I228A receptors, with decreased Імах, slow onset and slow desensitization as 
compared to WT, mCPBG responses appeared normal (Table 3.2, Fig 3.3). In 
comparison to fold changes seen in radioligand binding assays, smaller fold changes were 
seen in EC50 values o f  5-HT and mCPBG (~ 10 fold and 16 fold respectively).
In oocytes expressing I228A receptors, mCPBG was remarkably more efficacious 
than 5-HT. This caused a change in rank efficacy to mCPBG »  5 - Н Т »  2-Me5-HT (Fig
3.3). W hile the average Імах mCPBG levels for this mutation were 13.5 ± 1.5цА, Імах 5-нт
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levels were significantly reduced to ~ 0.5 ± 0.1 цА in the same oocytes. However, the Імах 
mCPBG value was not significantly different than that obtained for the WT receptor (Table 
3.2). These data indicate a decrease in efficacy o f  5-HT and not mCPBG on I228A 
receptors. Application o f 2-Me 5-HT produced no detectable currents in these oocytes at 
concentrations up to lOmM. Therefore, an EC50 value o f  2-Me 5-HT could not be 
determined for I228A receptors. These data indicate that I228A mutation selectively 
alters gating o f the receptor by 5-HT and not wCPBG. This selective role is further 
supported by the significantly reduced W s -h t  value (Table 3.2) with no concurrent 
reduction in BMax value (Table 3.1).
3.4.6 D229A receptors:
D229A receptors caused an 8 fold change in K<j value o f granisetron, possibly 
indicating an interaction o f  D229 with granisetron (Table 3.1). Similar to the selective 
effect observed for mutations o f F226 and 1228 residues, a 140 fold change in K. o f 5- 
HT, with no significant change in K, o f mCPBG was seen for D229A receptors (Table
3.1). Similarly, in electrophysiological assays o f D229A receptors, a 12.5 fold change in 
EC50 was observed for 5-HT, while no significant change was noted for /wCPBG. These 
data suggest that D229 is selectively involved in binding to 5-HT, but not mCPBG.
In order to determine if  D229A receptors affect gating, relative efficacies were 
compared in Xenopus oocytes. D229A receptors displayed Імах values identical to WT 
(Table 3.2). The EC50 value o f 2-M e-5-HT was 10.3 ±  О.брМ, not significantly different 
from WT. The rank efficacy for D229A receptors was identical to WT: 5-HT> mCPBG
»  2-Me 5-HT (Fig 3.4). The overall data indicate that D229A receptors alter binding to 
5-HT and do not alter gating o f the receptor.
3.4.7 S233A and S233T receptors:
S233A receptors ablated both binding and function (Table 3.1 and 3.2). 
Immunofluorescence experiments revealed that S233A receptors were not expressed on 
the cell surface (Fig 3.6). However, fluorescence was detected in permeabilized cells 
indicating either incompletely or incorrectly assembled subunits that remain 
intracellularly located. These data suggest that S233A mutation affects receptor assembly 
and/or trafficking to the cell membrane.
The S233T receptors were indistinguishable from WT receptors in both 
radioligand and electrophysiological assays (Table 3.1 and 3.2). To confirm that a role in 
gating was not involved, relative efficacies were also determined for the S233T mutation. 
The rank efficacy was unaltered for S233T receptors as compared to W'T receptors (Fig
3.4). The Імах values were also largely unaffected as shown in Table 3.2.
3.4.8 Y233A and Y234F receptors:
Similar to S233A receptors, Y233A mutation ablated binding and function. 
Imm unofluorescence data showed that Y233A mutation does not express on the cell 
surface, but remains intracellularly located (Fig 3.6). Thus Y233A mutation affects either 
receptor assembly and/or trafficking to cell surface.
To further study the Y234 residue, the conservative Y234F mutation was 
evaluated. An 11 fold increase in IQ value o f  granisetron as compared to WT was seen,
suggesting a possible interaction between Y234 and granisetron (Table 3.1). Large fold 
changes in Kj values o f both 5-HT (185 fold) and wCPBG (125 fold) were noted (Table
3.1) even for this conservative mutation, indicating a possible interaction o f Y234 with 
both agonists. Only moderate changes in EC 50 values were seen in electrophysiological 
assays o f  Y234F receptors (Table 3.2).
Relative efficacy comparisons revealed that the rank efficacy for Y234F receptor 
was significantly altered to mCPBG> 5 -H T » >  2-M e5-HT (Fig 3.2). The average Імах 
mCPBG value for Y234F (16.8 ± 1.9цА) was higher than the IMax 5-нт value (13.3 ± 1.5цА) 
(Table 3.2). This data indicates that either an increase in efficacy o f wCPBG relative to 5- 
HT or a decrease in efficacy o f  5-HT. The EC 50 value o f 2-M e5-HT for Y234F (11.1 ± 
1.4|iM) was unaltered compared to WT, while the relative efficacy o f 2-Me 5-HT was 
drastically reduced (0.019 ± 0.001), in comparison to WT receptors (Fig 3.4). These data 
indicate that residue Y234 plays a role in gating o f  the 5-HT3R.
3.4.9 Docking o f 5-HT, amCPBG  and granisetron to the M urine 5-HT3AR model:
Fig 3.5 shows docking o f agonists mCPBG, 5-HT and antagonist, granisetron to 
the murine 5-H TiaR model. No constraints based on the experimental data were applied 
while performing these docking calculations. All ligands are docked in the binding 
cavity previously described for 5-HT?Rs (Maksay et al., 2003, Reeves et al., 2003) The 
presence o f  numerous aromatic residues (W90, W 183, Y143, Y153, Y234, and F226) and 
acidic residues (E225, E236, D229) at the binding interface suggest that basic ligands can 
form both salt bridges and cation-71 interactions at the binding site. The interactions are 
also highlighted in Table 3.3.
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The docking calculations resulted in two possible models for mCPBG with nearly 
equal energies. The first model o f mCPBG binding ( ‘1’) is shown in Fig 3.5 C. In this 
case, the guanidino group forms salt bridge with D229. Tyrosines Y153 and Y234 can 
form hydrogen bonds and/or are involved in cation-я interaction with the guanidino 
group. W183 is also part o f  this aromatic pocket. The chloro group o f  raCPBG is near 
F226 in this model. The following interactions occur in the second model, ‘2 ’ (Fig 3.5 
D): The guanidino group forms a salt bridge with E236, while it is also involved in a 
cation-7i interaction with F226 and Y234. The aromatic ring o f mCPBG lies nearly 
parallel to W 183 producing weak n -n interaction. Aromatic residues, W90 and Y153 are 
also in close proxim ity o f the aromatic ring and the chloro group.
M ost frequent docking position o f 5-HT (Fig 3.5 B) forms similar interactions to 
that observed for the second mCPBG docking model. The amino group is intercalated 
between the aromatic F226 and Y234 residues, while it is salt bridged with E236. The 
first difference between the interactions o f the two agonists is that the OH group o f 5-HT 
is able to form a hydrogen bond with D229. D229 does not form an interaction with 
mCPBG in model ‘2 ’, while it forms a salt bridge interaction in the model ‘Г . Secondly, 
Y153 can form a hydrogen bond with mCPBG in one docking position ( ‘ I s) and does not 
in the other (‘2 ’).
Fig 3.5 A shows the antagonist granisetron with the lowest energy o f docking. Its 
aromatic rings are inserted to the hydrophobic region o f W 183, W90 and Y153. Its 
carbonyl group can interact with D229, while Y234 can form a hydrogen bond with 
pirazol nitrogen. The bicyclic ammonium ion can interact with N128 and E236.
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3.4.10 Comparison of results from docking studies with loop С mutagenesis:
3.4.10.1 Interactions of 5-HT:
Docking calculations predict that residues F226, D229 and Y234 from the loop С 
region form interactions with the agonist 5-HT (Table 3.3). The radioligand and 
electrophysiological data for mutations at these positions suggest that these residues 
interact with 5-HT. Thus, the experimental data for F226, D229 and Y234 are in good 
agreement with these predictions.
3.4.10.2 Interactions of mCPBG:
Two possible binding modes for wCPBG were obtained, with substantial 
differences in specific interactions. Model 1 (Fig 3.5C) predicts interactions o f  mCPBG 
with F226, D229, Y234 and Y153. All o f these interactions have been demonstrated for 
5-HT but not mCPBG (For Y153, see reference 19). This model also shows an interaction 
with W183 (loop B). mCPBG interactions have been postulated by earlier studies for 
W183 and E236 (Schreiter et al., 2003; Spier and Lummis, 2000). Our data support 
interactions at F226 and Y234, but the data for D229 are unsupportive o f model 1. In 
addition, although model 1 predicts the same interacting amino acids as 5-HT, the nature 
o f these interactions are different (Table 3.3). Specifically, a cation-л interaction rather 
than a 7t-7i interaction is predicted for W183, a n~n interaction rather than a cation-я 
interaction at F226 and a salt bridge rather than a hydrogen bond at D229. In contrast, 
model 2 (Fig 3.5D) predicts some differences in interacting amino acids, but, for 
overlapping residues, the type o f interaction is identical (Table 3.3). The first difference 
is that in this model, D229 does not produce specific interactions with mCPBG. Thus,
82
model 2 would accurately predict a change in binding affinity o f  5-HT but not mCPBG 
on D229A receptors, as supported by our data.
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3.5 Discussion:
3.5.1 Residues involved in mediating binding and gating by 5-HT:
The docked model o f 5-HT shows two aromatic residues, F226 and Y234; and 
two acidic residues, D229 and E236 from loop С participating in important interactions 
with 5-HT,
A cation-л interaction between F226 and 5-HT is indicated in the docked 5-HT 
model. The results for F226 mutations support a role o f F226 in both binding and gating. 
Considering the gaps in the sequence alignment o f the loop С region (Fig 3.1), F226 in 
the mouse 5-H T3asR  appears homologous to Y 190 o f the nAChR orR, which has been to 
be important for binding and/or gating (Akk et al., 1999; O 'Leary and White, 1992; 
Tomaselli et al., 1991). More importantly, crystal structures o f AChBP bound to 
carbamylcholine and nicotine indicate a hydrogen bond forms between the homologous 
residue (Y185) and К 139 (loop B) in the ligand-bound confirmation (Celie et at., 2004)
Our data indicate a role for D229 in binding o f  5-HT to the 5-H T3asR , but not in 
gating. This observation is supported by the docked 5-HT model which indicates a 
hydrogen bond between D229 and 5-HT. D229 is homologous to С 193 in the mouse 
nAChR, which has been identified as critical in the binding site o f nAChR by 
photoaffmity labeling and mutagenesis studies (Dennis et al., 1988; Kao et al., 1984; 
M ishina et al., 1985). The homologous С 188 in the AChBP crystal structure has been 
shown to be in contact with nicotine (Celie et al., 2004).
Mutation o f  Y234 to alanine ablated function, probably by preventing proper cell 
surface expression. In contradiction to these results, authors o f a recent study reported
that Y234A receptors were expressed on the cell surface (Price and Lummis, 2004). This 
difference could be due to expression levels below our level o f  detection or the use o f 
different antisera in the said study. Our data indicate a role for Y234 in mediating binding 
and gating by 5-HT. In accordance with these results, docking studies show a cation-л 
interaction between 5-HT and Y234. A recent crystal structure o f the AChBP shows that 
the homologous residue (Y192) makes an aromatic contact with nicotine (Celie et al., 
2004). Residues homologous to Y234 are strictly conserved as aromatic throughout the 
family (Fig 3.1). Separate lines o f evidence have implicated the homologous Y198 in the 
nAChR in binding o f  acetylcholine and/or gating (Akk et al., 1999; O'Leary and White, 
1992; Tomaselli et al., 1991). The homologous Y205 in the 02 GA BA aR has been shown 
to be facing into the GABA binding pocket (W agner and Czajkowski, 2001). Thus data 
from multiple receptor types support a key role for Y234 in binding and gating 
mechanisms.
In addition to F226, D229 and Y234, the 5-HT docked model also indicates 
potential interactions with W183 and E236. There is strong evidence for a cation-л 
interaction between the amino group o f 5-HT and W183 (Beene et al., 2002). While our 
5-HT docked model shows а я-л interaction between 5-HT and W 183, it should be noted 
that a small rotation o f  the carbon chain o f 5-HT would re-align the amino group, 
permitting a cation-л interaction with W183. We hypothesize that the conformational 
mobility o f the saturated carbon chain o f 5-HT may allow a conformation where the 
amino group is not salt bridged with E236, but forms a cation-л interaction with W183. 
This mobility could play a role during the activation o f the 5-HT3R. E235 has been
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previously shown to be within lnm  o f the ligand-binding site (Schreiter et al., 2003). Our 
5-HT docked model corroborates this conclusion by showing a salt bridge formation 
between E236 and the amino group of 5-HT. E225 is another acidic residue which has 
been postulated to be involved in both binding and gating o f the 5 -HT3R (Schreiter et al.,
2003). Our partial agonist data support a role o f  E225 in gating. Since the docking 
models do not support a binding interaction o f E225 with any docked ligand, we propose 
that E225 may have a moderate involvement in gating, but not binding in the 5-HTiR.
3.5.2 Residues involved in binding of //iCPBG:
Two models were predicted by docking calculations for wCPBG. The combined 
results for D229 support model 2 for wCPBG binding. Thus the mCPBG/ 5 -HT3R 
interactions are similar to 5-НТ/ 5-HTjR interactions, with D229 being a major point of 
differences. The types o f  interactions for overlapping residues in wCPBG model 2 are 
same as those in the 5-HT model.
3.5.3 M utations o f 1228 selectively modulate gating by 5-H T and not /wCPBG:
1228 appears to be selectively involved in 5-HT m ediated gating. The exact 
mechanism behind the 5-HT selective effect for 1228 is unclear. Our docking studies 
show that 1228 is within 4A of docked 5-HT and /wCPBG and may interact with either 
ligand. However, only an interaction with 5-HT is supported by experimental data. One 
explanation for the apparent discrepancy in docking and experimental data for 1228 may 
be that this residue may interact with 5-HT in a different confirmation o f 5 -HT3R.
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3.5.4 Granisetron binding to 5 -HT3R:
Previous studies have implicated W183, E236 and W 90 as interacting with 
granisetron (Schreiter et a t ,  2003; Spier and Lummis, 2000; Yan et al., 1949). Results of 
this study indicate that D229 and Y234 also interact with granisetron. The granisetron- 
docked model indicates close interactions (< 4A) for residues identified via mutagenesis 
studies, although specific interactions are indicated only for F226 and Y234. D229 forms 
a polar interaction, while Y234 forms a hydrogen bond with the pirazol nitrogen 
However, our experimental data do not support an interaction between granisetron and 
F226. This discrepancy may be due to the state o f  the receptor modeled by the homology 
model. It has been suggested that the AChBP, on which this model is based, may 
represent the open state o f  the receptor (Beene et al., 2004). In contrast, granisetron is 
thought to bind to the closed or “ground state” o f the receptor. In the transition between 
closed and open states, significant rearrangements are thought to occur within the binding 
site including movement o f  the С-loop, Such rearrangements are supported by crystal 
structures o f  the AChBP, where the Y185 (homologous to F226) forms a hydrogen bond 
with K139 (from loop B) in the ligand-bound confirmation (Celie et al., 2004). The result 
o f  such rearrangements may close the binding cavity, possibly through movement o f the 
С loop toward the E loop. If  the homology model more accurately represents the open 
state o f the receptor, then the docked mCPBG and 5-HT models would be expected to 
better fit the empirical data than would the granisetron model.
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3.5.5 Final conclusions:
Results o f  this study support an emerging picture o f  5-FIT and /wCPBG mediated 
interactions with the loop С region o f the 5 -HT3R. Our results identify the molecular 
determinants o f differential action mediated by these two diverse agonists. Partial agonist 
data also show that the identified loop С residues play a more involved role in gating. In 
agreement with this conclusion, recent ligand bound crystal structures o f the AChBP 
show that the loop С rearranges and closes down on the bound agonist (Celie et al.,
2004).
M utational studies o f nAChR support a role o f binding site residues in stabilizing 
the open state o f  the receptor (Akk et al., 1999; Chakrapani et al., 2004; Karlin, 2002; 
Sine, 2002). Similarly, in the 5-HT3R, E225, F226 and Y234 appear to be involved in the 
gating mechanism o f 5-HT and mCPBG, possibly through stabilization o f the open state 
o f the 5-HT3AR via direct interaction with either agonist. In contrast, 1228 seems to 
selectively stabilize the 5-HT bound open state o f the receptor, while minimally 
interacting with mCPBG. This conclusion provides the simplest explanation o f how a 
gating residue can be ligand (5-HT) specific.
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Figure 3.1 Sequence alignment of the purported loop С region of the 5-HT3As 
receptor with other members of the family
The amino acid sequence o f the mouse 5-hydroxytryptamine-type 3 A short isoform 
receptor (m 5-HT3ASR) was aligned with sequences o f  other ligand-gated ion channel 
receptors and acetylcholine binding protein (AChBP) using a multi-sequence ClustalX 
alignment method. The alignment o f the purported “loop C ”  region across various 
members o f the LGIC family and AChBP is shown. Conserved residues are bold and 
shaded gray. Residues found to be important in this study are marked bold and italicized 
in the mouse 5-HT3asR. The numbers at the end indicate position as measured from the 
N-terminal, excluding the initial methionine in the protein sequence o f  the mouse 5- 
H T jasR- Residues in the mouse 5-HT3AsR that are mutated to alanines are denoted with 
an ‘A ’ above each wild-type residue.
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Figure 3.2 Electrophysiological characterization of W T, E225A, F226Y and Y234F 
receptors expressed in Xenopus laevis oocytes
Characteristics o f inward currents elicited by application o f agonists at supra-maximal 
concentration are shown for each receptor type. The traces shown for WT and mutant 
receptors were obtained from the same oocyte. Traces shown are representative o f 
multiple experiments (n >4). The solid bar on the top o f each trace denotes time o f drug 
exposure, type o f agonist used and its concentration. The rank efficacy for each receptor 
type is also shown. Note that no currents could be detected upon application o f 2-Me 5- 
HT in F226Y and I228A Rs.
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Figure 3.3 Electrophysiological characterization of m utations which differentially 
interact with 5-HT and wiCPBG.
Inward currents elicited by application o f agonists at supra-maximal concentration are 
shown for D229A, I228A, Y153A and Y153F mutations. These mutations show 
differential effects for 5-HT and /wCPBG in binding and electrophysiological assays. In 
addition, I228A mutation also selectively alters 5-HT induced response characteristics. 
The traces shown for wild-type and mutant receptors were obtained from the same 
oocyte. Traces shown are representative o f multiple experiments (n >4). The solid bar on 
the top o f each trace denotes time o f drug exposure, type o f agonist used and its 
concentration. The rank efficacy for each receptor type is also shown.
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Figure 3.4 Changes in relative efficacies of 2-Me 5-HT and mCPBG for wild-type 
and mutant receptors.
The bar graph shows a comparison o f 1махлвоішЛмах5-нт (relative efficacy) for WT and 
mutant receptors. For each receptor type, maximal currents elicited by each agonist 
(mCPBG, 2-Me 5-HT) were directly compared to those elicited by 5-HT on a single 
oocyte. Results shown are from multiple such experiments. Error bars indicate S.E. 
Empty bars indicate 5-HT, dark grey bars indicate mCPBG and light grey bars indicate 2- 
Me 5-HT. The relative efficacy o f 5-HT is 1.00 for each receptor type since currents for 
all agonists were normalized to Імах5-нт. For WT receptors, the relative efficacies of 
mCPBG and 2-Me 5-HT were 0.93 ± 0.01 and 0.12 ± 0.002, respectively, yielding a rank 
efficacy o f 5-HT > mCPBG »  2-Me 5-HT (Fig 3.2). Changes in rank efficacy for mutant 
receptors (shown in Fig 3.2 & 3.3) are reflected in this bar graph. * indicates significantly 
different from WT (p< 0.05). N.D indicates relative efficacy o f 2-Me 5-HT could not be 
detected.
L
Figure 3.5 Docking of 5-HT, /mCPBG  and granisetron to the murine 5-HT3AR 
model.
M odeling o f the extracellular domain o f the murine 5-HT3aR and ligand docking were 
performed as described in “M aterials and methods” . The figure shows the docked model 
o f (A): granisetron and (B): 5-HT. Two possible docked models were obtained for 
mCPBG and are shown as: (C): Model ‘1’ and (D): Model ‘2 ’. The experimental results 
support the Model ‘2 ’ obtained for mCPBG.
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Figure 3.6 Localization of С-terminal FLAG tagged wild-type and loop С mutant 
receptors b y  imm unofluorescence.
To determine the presence o f  wild-type (WT) and mutant receptors on the cell-surface, 
FLAG tagged W T or mutant receptors were transiently expressed in tSA  201 cells and 
characterized using immunofluorescence. Fixed cells were initially incubated with an 
anti-mouse anti-FLAG primary antibody. Intracellular localization was determined using 
Triton X-100. Cell surface or intracellular localization was determined by using an anti­
goat Rhodam ine-conjugated secondary antibody. All images were acquired using 20 X 
magnification lens coupled to a digital camera. Scale bar indicates lOjum. The first 
column shows the localization in absence o f Triton, and the second column shows the 
localization in the presence o f Triton, i.e. permeabilized cells. A negative control (mock 
transfected cells, no primary antibody) with and without Triton is also included at the top. 
Images obtained show that WT and F226A receptors are expressed on the surface, while 
S233A and Y234A mutations remain intracellularly located.
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Table 3,1 Effects of m utations on 5-HT3AR radio-ligand binding
Ligand affinities o f wild-type (WT) and mutant receptors were determined as described 
in “Materials and m ethods.” Expression levels o f  receptors are indicated as Вмах values. 
Each value was obtained using at least 4 determinations at each concentration, and is 
reported as mean ± S.E. Fold changes with a -  sign indicate Kd or Ki values lower than 
the corresponding value obtained for WT. a significantly different from WT (p< 0.05). 
N.B: No binding detected up to 300nM of [3H] Granisetron. * F.C: Fold change. Dash 
signs indicate that values could not be determined since no specific binding to [ H] 
granisetron could be detected.
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Table 3.2 Effects of mutations on 5-HT3AR electrophysiology
EC50 and Hill coefficient values o f serotonin and wjCPBG for wild-type (WT) and mutant 
receptors were determined as described in “Experimental Procedures.” Each value was 
obtained using at least 4 determinations at each concentration, and is reported as ± S.E. 
Імах values indicate average maximal currents elicited by 5-HT for the respective 
receptor. 5-HT was found to be the most efficacious agonist in all cases except F226Y, 
I228A and Y234F, where m C PBG was more efficacious. Dash signs indicate that the 
values could not be determined since the receptor was not functional, a significantly 
different from WT (p< 0.05). N.R indicates that that no responses could be detected up to 
ImM o f 5-H T/w C PB G . * F.C: Fold change.
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Table 3.3 Docking calculations for models of 5-H T, 2-Me 5-H T, »iCPBG  and 
Granisetron
Modeling o f  the extracellular domain o f the murine 5-H TjAR and ligand docking were 
performed as described in “M aterials and methods” . The results are also represented in 
Figure 3.5. Interactions predicted for 5-HT, 2-Me 5-HT, granisetron and mCPBG (model 
‘1’ and model ‘2 ’) are shown in the table. HB: Hydrogen bond, SB: Salt bridge, CP: 
Cation-тс interaction, PP: n - n  interaction, + : Within 4A o f docked ligand.
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Chapter 4: 5-HT3R binding of lerisetron: an interdisciplinary approach 
to drug-receptor interactions
4.1 A bstrac t
The synthesis and biological evaluation o f lerisetron-based molecular probes to 
investigate the 5 -HT3R binding site are described. A structure-activity relationship (SAR) 
study, which involved distance and electronic param eter modifications o f lerisetron's N- 
benzyl group, resulted in the discovery o f a partial agonist.
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4.2 Introduction
Our research efforts have been focused on the design, synthesis, and use o f novel 
molecular probes to gain a better understanding o f the underlying mechanism(s) o f  drug- 
receptor interactions ([D -R ]). Particularly, how do drugs with dissimilar activities (i.e., 
agonist, reverse agonist, or partial agonist) compare in terms o f  binding to the receptor 
and how does this affect the resultant activity. Unfortunately, methods available to study 
specific [D -R], especially in membrane-bound receptors, are somewhat limited. In our 
efforts to contribute to the general understanding o f [D -R], we have focused on the 
serotonin type-3 receptor, (5-HTjR), which is a membrane-bound, ligand-gated ion 
channel receptor. Clinically, 5 -HT3R antagonists are used for cancer treatment-induced 
emesis; however, current research strongly suggests a potential use o f 5 -HT3R ligands in 
treatment o f cardiovascular disease, anxiety, and drug addiction (Glenn and Green, 1989; 
Lovinger, 1999; W ilson et al., 1990).
The goal o f SAR studies for a series o f drug molecules has been the development 
o f  pharmacophore models. Hibert and co-workers established one o f  the earliest models 
for 5 -HT3R antagonists, based on a conformational analysis study o f  23 analogues and 
subsequent superimposition o f the more energetically favored conformers (Hibert et al., 
1990). The original three point model was comprised o f  (1) a basic nitrogen, (2) a 
carbonyl group participating in a hydrogen bonding interaction and coplanar with (3) an 
aromatic ring. The 5-HT3R antagonist model has since been refined to include another 
lipophilic interaction and a second hydrogen bonding interaction (Cappelli et al., 19^9;
Clark et al., 1993; Rival et al., 1998; Swain et al., 1992). Figure 4.1 shows the current 
refined pharmacophore model o f 5 -HT3R antagonists. Pharmacophore models for partial 
agonist activity have also been reported (Cappelli et al., 1998; Daveu et al., 1999; Dukat
et al., 1996).
The aim o f this study was to evaluate if  there is an electrostatic component in the 
N1- substitution in lensetron, which is a novel benzim idazole-rm g containing 5 -HT3R 
antagonist (see Figure 4.1). We have employed SAR studies to elucidate such a possible 
role o f the N 1-substitution. Electrostatic interactions have a strong dependence on both 
electronic param eters and distance. Thus, eight N1-substituted-2-piperazinyl 
benzimidazole analogues have been designed by either varying the electronic nature o f 
the aromatic ring from electron rich to electron poor or lengthening the distance between 
the aromatic ring and N1 nitrogen atom.
In addition to understanding the role o f N1 substituent o f lensetron, results from 
this study will also be used to design ‘active pairs’ o f lerisetron analogs. An active pair is 
two analogs displaying at least low micromolar activity and differing only by the 
presence or absence o f a functional group. Such active pairs can then be evaluated on 
mutant 5-НТз receptors to understand the interaction o f Leristeron with the 5-HT3R 
(Venkataraman et al., 2002a).
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4.3 Materials and Methods:
4.3.1 Chemical synthesis:
All target molecules were prepared according to a method reported previously by 
Orjales et al. (Orjales et al., 1997) with only slight modification. This general two-step 
synthesis is outlined in Scheme 1. Commercially available 2-chlorobenzimidazole (1 
equiv), in dry DM F was treated with a slight excess o f NaH (1.1 equiv). After stirring for 
1 h at room temperature, 1 equiv o f the appropriate alkyl halide (Br, Cl) was added 
slowly and the reaction mixture heated under reflux for >5 h (reaction was monitored by 
TLC). Reaction product was partitioned between H20  and methylene chloride; organic 
layer was dried (Na2SC>4) and concentrated in vacuo. The solid residue was purified by 
flash chromatography, which afforded the corresponding TV-substituted 2- 
chlorobenzimidazole intermediates in good yield. The final step involved a nucleophilic 
substitution o f  the 2-chloro group by piperazine at high temperatures. The reaction was 
performed neat using 4- to 10-fold excess piperazine (water soluble) and typically heated 
for short periods only (30-45 min). Similar workup afforded a residue that was purified 
by either crystallization or chromatography. The yields ranged from 40 to 95%. All 
compounds were characterized by NMR, MS, HRMS and/or elemental analysis, or were 
identical to literature reports.
4.3.2 Preparation of cRNA and expression of receptors:
Complementary RNA for the human S-HTsaR was synthesized in vitro from a 
linearized template using mMACHINE RNA transcription kit (Ambion, TX, US). Mature
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Xenopus laevis were anesthetized by submersion in 0.22% Tricaine methane-sulfonate 
(Sigma Chemicals, MO, US) and oocytes surgically excised. The follicular cell layer was 
removed by treatment with 1.5% collagenase II (Sigma Chemicals, MO, US) for l-2 h  at 
room temperature. Oocytes were injected with lOng o f RNA in 50mL nuclease-free water 
and incubated at 19°C in calcium-free ORII medium (82.5mM  NaCl, 2.5mM KC1, ImM 
MgCl2, 5mM HEPES, pH 7.4).
4.3.3 Electrophysiological recording:
After 2 -5  days o f incubation, electrophysiological recording was carried out in a 
specially designed chamber. Oocytes were perfused at a rate o f approximately 8mL/min 
with ND96 recording buffer (% m M  NaCl, 2.0mM KC1, 1.8mM C'aCl2, ImM  M gCl2, 
5mM HEPES, pH 7.4). Test compounds were diluted in ND-96 buffer and applied to the 
oocytes using a gravity-fed bath perfusion. Membrane currents were studied under two- 
electrode voltage-clam p conditions, at a holding potential o f  -60m V , using W arner 
instruments Oocyte Clamp, OC-725 amplifier. Data were analyzed using Graph-Pad 
prism software. The data for the antagonists were normalized to the currents elicited by 
ІцМ  5-HT.
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4.4 Results and discussion:
Table 4.1 contains the biological activities o f  the target molecules. All antagonists 
( 1 8 )  displayed high binding affinity for the human 5-HT3AR ranging from 25 times less 
to nearly equipotent to lerisetron. Analogues p-methoxy (6), p-m ethyl (7), p-fluoro (8) 
contain substituents that vary the electronics o f the N1 benzyl aromatic ring from electron 
rich to electron poor. The p-methoxy derivative was most active, whereas, the p-fluoro 
derivative was least active. A linear regression analysis including the des-benzyl 
derivative (i.e., 1, 2, 6, 7, and 8 ) provided a significant correlation between electronics 
(R-induclion , r2= 0 .8413,/3=0.0282, F—15.91) o f the corresponding N 1-substituents and 5- 
НТзаЯ activity. Lengthening the distance between the aromatic ring and the N1 nitrogen 
atom by either one or two carbon atoms resulted in a 20-fold decrease in receptor binding 
activity (see Fig. 4.2). The naphthyl analogue (5) is 4 times less active than the benzyl, 
suggesting that the internal aromatic ring might be utilized for receptor binding activity. 
Preliminary SAR results indicate both an electronic and distance component to the benzyl 
interaction. Thus, the present SAR study supports our model that places R91 in close 
proximity to the benzyl group o f lerisetron.
Replacement o f the ІѴ-benzyl group with an /V-allyl group resulted in a compound 
possessing partial agonist activity (9). This activity could be blocked by tubocurarine, a 
competitive antagonist. This discovery provides us with a unique pair o f  active analogues 
that can now be used to probe partial agonist activity. If  the /Vr-benzyl and TV-allyl groups 
are similarly located, then the conversion o f lerisetron into a partial agonist would
support a model that suggests this 5 -HT3R antagonist spans both partial agonists and 
antagonist binding sites. Another such active pair o f analogs identified from this study is 
that o f lerisetron and des-benzyl analog. This active pair has been utilized in mutagenesis 
studies o f the 5-HT3R to elucidate functional group interactions o f lerisetron with Loop E 
residues o f 5-HTjR (Venkataraman et al., 2002a) Using such active pairs o f analogs and 
mutagenesis studies, a 5-HTiR model that incorporates all three types o f ligands 
(agonist, antagonist, and partial agonist) can be potentially developed.
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Scheme 4.1: 
benzimidazoles.
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Table 4.1: Inhibition of serotonin-induced response by compounds 1-9
Values are mean o f  at least three experiments, standard error (S.E) is given 
parentheses.
( отпpounds N t  ЧііЫ ііііспі <R) .SrHTjR inh ib ition4 K, (nM )
<> V| (ІѲ.ОД 
19.21 1*0.84)
|H,C)j ^  7.4.1 ( ± 1.9 )
:> 7.%
I 41 (-rO  V il€0
- H C - (  \ - O C H ,  0.42 ( = 0 .0 7 )
H a C - i  i — F 5-21 1*2.24)
H  .. Ec:w= 0 24 ( ± 0 .0 5 ) u M
litticacy = 30%
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Chapter 5: Role of the 5-HT3B subunit in the 5-HT3AB receptor binding 
site
5.1 Abstract
5-HTj receptors belong to the Cys-loop superfamily o f  ligand-gated ion channels. 
Depending on subunit composition, 5-HT3 receptors can assemble as homomeric 5-НТзд 
or heteromeric 5-НТздв receptors. The contribution o f  the N-terminal o f  the В subunit to 
the formation o f  5-НТздв receptors is unknown. In this pilot study, we constructed A­
B N-terminal chimeric receptors to explore such a contribution o f the В subunit. All 
chimeric receptors were evaluated by radioligand binding and immunofluorescence 
assays. We found that the chimeric receptors were challenging to characterize since 
substitution o f  even small stretches o f the N-terminal o f the В subunit with that o f the A 
subunit disrupts cell surface assembly o f the chimeric receptor. Even though the chimeric 
receptors do not express on the cell surface, they show binding to granisetron, with 
altered affinities. Overall, our data indicate that in addition to signals in the 
transmembrane region, the N-terminal o f the В subunit has several important subunit 
contacts and/or assembly signals which are essential for formation o f cell surface 
receptors.
5.2 Introduction
The 5-HT3R (5-hydroxytryptamine3 receptor) belongs to the ligand-gated ion 
channel (LGIC) superfamily that is also comprised o f the nicotinic acetylcholine, 
GABAa and glycine receptors (Arias, 2000; Chebib and Johnston, 1999; Corringer et al., 
2000; Reeves and Lummis, 2002). The receptors in this family are membrane-bound 
pentamers and mediate fast synaptic transmission. These receptors have an extracellular 
N-terminal region (consisting o f the ligand-binding site), four transmembrane regions 
(M1-M4) and an extracellular С-terminal region. Depending on subunit composition, the 
ligand-gated ion channel receptors can assemble as homomers or heteromers. In case o f 
the 5 -HT3R, two subunits, 5-HTiA and 5 -HT3B have been cloned. Unlike the 5 -HT3A 
subunit, 5 -HT3B subunits cannot form functional homomeric receptors (Davies et al., 
1999). However, 5 -HT3A and 5-HTiB subunits can со-assemble to form functional 
heteromeric receptors. The 5-НТ3дв heteromers show distinct pharmacological and 
functional properties as compared to the 5-HT3A heteromers.
The m olecular determinants o f function in the 5-HT3A and 5-H T3Ab receptors are 
not clearly understood. The role o f the transmembrane regions o f  the 5-НТзВ subunit has 
been explored by two studies. One study concluded that the В subunits could not form 
cell-surface receptors since they were retained inside the cell due to an ER retention 
signal between the transmembrane regions I and II o f 5-НТзВ subunit (Boyd et al., 2003). 
Transplantation o f this signal (CRAR) into the homologous region o f  5-HT3A also leads 
to ER retention o f the A subunits, until they are rescued by co-assembly with wild-type 5- 
HT3A subunits. The mutation o f this ER retention signal in 5-HTjB to the homologous
sequence in the A subunit (i.e. from CRAR to SGER) does not lead to cell surface 
expression. These data suggest the additional presence o f other signals, or mechanisms 
that control the cell surface expression o f 5-HT3bR s. Another study which explored the 
role o f the transmembrane regions o f the В subunit using A-В chimeric receptors 
reported the importance o f a ‘HA stretch’ o f residues in the large M 3-M 4 cytoplasmic 
region o f the 5-HT3A subunit (Kelley et al., 2003). The replacement o f  three arginine 
residues unique to the HA-stretch o f the 5-HT3A subunit by homologous residues in the 
5-HT3B subunit increased single-channel conductance 28-fold. However, the role o f the 
N-terminal o f the В subunit in assembly and/or formation o f ligand-binding sites in the 
AB heteromeric receptors. When the amino-acid sequence o f the A and В subunits are 
compared, critical differences are seen in the N-terminal regions (in addition to 
differences in the transmembrane regions). In this study, we studied such a potential role 
o f the N-terminal o f the В subunit in the o f the heteromeric 5-HT3abRs by constructing 
chimeric A-В receptors.
In this pilot study to understand the role o f the loops A-F o f  the В subunit, 
multiple N-terminal A-В chimeric receptors were constructed and evaluated by 
radioligand binding and immunofluorescence assays. W e found that the chimeric 
receptors were challenging to characterize since substitution o f  even small stretches o f 
the N-termmal o f  the В subunit with that o f the A subunit disrupts cell surface assembly 
o f the chimeric receptor. Even though the chimeric receptors do not express on the cell 
surface, they show binding to granisetron, with altered affinities. Overall, our data 
indicate that the В subunit has several important subunit contacts and/or assembly signals
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which are essential for formation o f cell surface receptors. Thus, it appears that both N- 
terminal and transmembrane regions o f the В subunit have important signals that regulate 
cell surface assembly o f the receptor.
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5.3 M aterials and Methods:
5.3.1 Chimera Construction:
The method developed for chimera construction is shown in scheme 5.1. For 
chimera construction, two fragments were initially synthesized using PCR. To construct 
each fragment two oligonucleotides were used. Oligonucleotides were designed such that 
an overhang o f  20 residues was produced in each fragment. These overhangs were 
complementary and produced the construct with the switch-point o f interest when 
annealed together. These fragments were further amplified using upstream and 
downstream oligonucleotides. Taq DNA polymerase was used to generate PCR product 
with 3 ’ A overhangs. These PCR products were ligated into pCR 3.1 ТА cloning vector 
(Invitrogen, С A, US). The ligation products were confirmed by restriction digests and 
sequencing.
5.3.2 Cell Culture and transfection:
?sA201 cells, a derivative o f human embryonic kidney cell line, were seeded at a 
density o f  5 x 10 cells/100mm dish. Cells were grown in DMEM medium containing 
10% FBS, 100 units/ml penicillin/streptomycin for 9 hours in 5% CO 2 and transfected 
with 10(ig human 5 -FIT3 cDNA per 100mm dish using the calcium phosphate technique. 
M edia was changed 12-14hrs after transfection. The cells were allowed to grow for 
another 24 hours and then harvested.
5.3.3 Binding assays:
Transfected cells were collected and washed twice with Dulbecco's PBS and 
resuspended in 1.0ml PBS/100mm dish. Cells were then homogenized and centrifuged at 
35 ООО X g for 30 minutes. Membranes were washed once more with PBS then 
resuspended in 1ml PBS/100 mm dish. Binding assays were performed in PBS in 
presence o f a protease inhibitor cocktail (Roche, MA, US). For Kd determinations, 100 (il
0 3o f homogenate was incubated at 37 С for 1 hour with varying concentrations o f [ H] 
granisetron (NEN, MA, US). For K, determinations, 100 ці o f  homogenate was incubated 
at 37°C for 2 hours with varying concentrations o f inhibitor and [ H] granisetron. Binding 
data were analyzed using GraphPad PRISM.
5.3.4 Two-electrode voltage clamp electrophysiology:
Xenopus laevis oocytes were used for this technique. Briefly, ovarian lobes were 
surgically removed from Xenopus laevis frogs and washed twice in Ca free Barth’s 
buffer [82.5mM NaCl / 2.5mM KC1 / ImM  M gCl2 / 5mM HEPES, pH 7.4] and gently 
shaken with l,5m g/m l collagenase (Sigma type II, Sigma-Aldrich) for 1 hour at 20-25°C. 
Stage IV oocytes were selected for microinjection. Synthetic cRNAs for WT and 
chimeric receptors were prepared using the mMESSAGE mM ACHINE™  High Yield 
Capped RNA Transcription Kit (Ambion, TX, US). Each oocyte was injected with 50nl 
cRNA at a concentration o f 0.2ng/nl. Oocytes were incubated at 19°C for 2 to 4 days 
before electrophysiological recording. Electrical recordings were made under 
conventional two-electrode voltage-clamp using an OC-725C oocyte clamp amplifier 
(W arner Instruments, CT, US) coupled to an online, computerized data acquisition
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system (Datapac 2000, RUN technologies, CA, US). Recording and current electrodes 
were filled with ЗМ KC1 and had resistances o f 1-2 m il. Oocytes were held in a vertical 
flow chamber o f  400pl volume and perfused with ND-96 recording buffer (% m M  NaCl / 
2mM KC1 /1.8mM  CaC h / I mM M gCb /5mM HEPES, pH 7.4) at a rate o f 15ml/min. All 
agonists were prepared in ND-96 buffer and applied at a rate o f  25ml/min using an 
electrical pump.
5.3.5 Immunofluorescence:
The chimera o f  interest was tagged at the C-terminal using the EGFP-N1 vector 
(Clontech, CA, US). This tagged chimera was expressed either alone or in conjugation 
with the human 5-HTjA subunit in tSA  201 cells using the Superfect® transfection kit 
(Qiagen, CA, US). The cells were grown on coverslips and fixed 24-30 hours transfection 
using 4%  para-formaldehyde. used was Anti-GFP antibody (Clontech, CA, US) was used 
as the primary antibody at a 1:200 dilution with or without 0.2 % Triton X-100. The 
secondary antibody was Cy3-conjugated goat anti-mouse (Jackson immunolabs, NC, US) 
diluted at 1:600. The cells on coverslips were mounted on glass slides and observed 
under a Olympus IX-70 microscope using the appropriate filter sets (Omega Optical, VT, 
US).
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5.4 Results and discussion:
In order to elucidate the role o f the 5-HT3B subunit in assembly and/or formation 
o f the ligand-binding site o f  AB receptors, chimeric receptors were constructed. The 
chimera design and switch points therein are explained in scheme 5.1 and figure 5.1, 
respectively. Initially 2 chimeras, A В and B A were constructed. These chimeras had 
switch points at positions 242 and 239 respectively. The A/В chimera bears the N- 
terminal from the A subunit and the transmembrane region is from the В subunit. Vice 
versa, the В/A  chimera bears the N- terminal from the В subunit, while the rest o f the 
protein is from the A subunit. These chimeric receptors, W T (homomeric A) receptors 
and heteromeric AB receptors were evaluated by saturation binding assays with [JH] 
granisetron. As shown in figure 5.2, the A ,В chimera showed a 2.5 fold increase in Kd, 
while the В/A chimera showed a 7.7 fold increase in BQ value. W hen the A/В chimera 
was characterized in competition assays, a 10 fold increase in K, value for 5-HT, a 25 
fold increase in Kj for MDL-72222 and a 4 fold fold change in K, value for wCPBG were 
noted as compared to WT receptor (Figure 5.3). In competition assays with the B/A 
chimera, much more drastic changes were observed (Figure 5.5). A 367 fold change in K, 
value for mCPBG was seen, whereas 5-HT could not displace the [ H] granisetron bound 
to the В/A chimera at concentrations up to 3mM. These changes indicate that the 
affinities o f  both 5-FIT and mCPBG were altered for the A/В and В/A chimeras.
The A, В and В/A chimeric receptors could not be functionally characterized 
when expressed in Xenopus oocytes. This could because o f  lack o f cell surface 
expression. The radioligand binding results for the A, В and В/A chimeras could be due to
binding o f granisetron to intracellularly located receptors. Such intracellularly receptors 
can be incompletely formed oligomers o f subunits which can still show high affinity 
binding to granisetron. In agreement with this, we also noted much lower specific CPM 
values in binding assays o f chimeric receptors compared to WT receptors (Data not 
shown). In order to characterize the cellular localization o f the A/В receptor, we 
constructed a GFP tagged A/В chimera. Figure 5.4 shows the immunofluorescence data 
for this receptor expressed in /SA 201 cells. GFP tagged A, В receptors can be detected 
only in triton-treated cells, indicating intracellular receptors but no surface expression. 
However, GFP tagged A В subunits can be rescued to the membrane when co-expressed 
with untagged A subunits (as shown by part D o f the Figure 5.4. These data suggest that 
that the A/В receptors do not express on the cell surface, presumably because o f the ER 
retention signal (CRAR) reported earlier. Similarly, the B A  chimera was also GFP- 
tagged and tested using immunofluorescence assays (data not shown). The results 
obtained were identical to those for the GFP tagged A В chimera. The GFP tagged B/A 
chimera did not express on the cell surface, but could be rescued by co-expression with 
untagged A subunits. The combined results suggest that signals for cell surface 
expression exist not only in the transmembrane o f the В subunit, but also in the N- 
terminal domain.
To further dissect the role o f the N-terminal domain o f the В subunit, we 
constructed a В/A pre-Cys chimera. In this chimera, the switch point was just preceding 
the signature Cys-loop o f 5-HTiR (see figure 1.1). In other words, this chimera has loops 
D, A and E from the В subunit, whereas loops В, C, F and the Cys-loop come from the A
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subunit. This chimera produced a 5 fold increase in IQ value for j 'H] granisetron (Figure 
5.2). In competition assays, the results seen were akin to those for B/'A chimera. mCPBG 
produced a 450 fold change in K; value, whereas 5-FIT could not inhibit [ H] granisetron 
binding at concentrations up to 3mM (Figure 5.6). Similar to the A/В and В/A chimeras, 
this chimera was also not functional in electrophysiological assays. These results suggest 
that even the presence o f the loops В, С and F o f the A subunit does not produce 
functional receptors. These data also indicated that loops D , A and/or E o f  the В subunit 
may be critical for cel 1-surface assembly. We therefore constructed individual loop 
chimeras, wherein individual loops from the В subunit were inserted into the homologous 
portions o f the A subunit. To this end, we constructed Loop D and Loop E chimeras. 
However, substitution o f  either loop D or Loop E ablated cell surface expression (Data 
not shown).
Our overall results indicate that the molecular determinants o f  assembly are 
spread throughout the N-terminal o f the В subunit. In addition to the ER retention signal 
(between TM1 and TM 2) reported earlier for the В subunit, m ultiple signals seem to exist 
in the N-terminal o f the В subunit. It is challenging to dissect the exact location o f such 
assembly signals or subunit contacts using the approach o f chimeric receptors. It may be 
possible to better decipher such signals employing point mutants o f  the В subunit, based 
on previous data from the 5-HT3AR. M olecular models o f  heteromeric AB receptors 
based on the AChBP can also be employed to guide such studies.
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Scheme 5.1 Chimera construction method
This scheme shows the details o f chimera construction as discussed in “M aterials and 
methods” .
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Figure 5.1 Switch points of A-В chimeric receptors
The N-terminal sequences o f the human A and В subunits are compared. Loops A-F are 
indicated by arrows. The Cys-loop is indicated by a solid bar preceding the Loop В 
region. The critical residues identified in the loops A-F o f  the A subunit are italicized. 
The dotted arrows show the switch points o f the chimeric constructs. The dotted arrow 
before the Cys-loop indicates the switch point for the pre-Cys chimera; while that at 
position 242 & 239 indicates the switch point for the A B and В/A chimeras, 
respectively.
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Figure 5.2 Radioligand binding to [ H] granisetron
Kd values were obtained employing saturation binding assays as explained in “Materials 
and m ethods” section. The ICd values for [3H] granisetron obtained for homomeric A and 
heteromeric AB receptors are compared with those obtained for A/'B, В/A and В/A pre- 
Cys chimeras. Error bars indicate standard error.
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Figure 5.3 Com petition assays of A/В chimeric receptors
This figure shows the fold changes in K, values o f 5-HT, wCPBG, d-tC and MDL 72222 
for the A, В chimeric receptor as compared to W T (5-HT3A) receptors. K, values were 
obtained as discussed in Materials and Methods. Error bars indicate standard error.
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Figure 5.4 Imm unofluorescence assays of the A/В chimera 
A and B:
Slide A indicates permeabilized cells expressing the A/В chimera under white light and 
slide В indicates the same cells under fluorescent light. The fluorescence observed in 
slide В indicates intracellular localization o f the A, В chimera.
С and D:
Slide С indicates non-permeabilized cells со-expressing the A 'B chimera and A subunit 
under white light and slide D indicates the same cells under fluorescent light. Non- 
permeabilized tSA 201 cells coexpressing the A В  chimera and A subunit show cell- 
surface expression as indicated by fluorescence in slide D.
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Figure 5.5 Com petition assays of В/A chimeric receptors
This figure shows the fold changes in Kj values o f 5-HT and mCPBG for В/A chimeric 
receptors as compared to 5-НТзА receptors. Kj values were obtained as discussed in 
M aterials and M ethods. Error bars indicate standard error.
f -  о  и
з :  со н
•А -ои
Com pound
Figure 5.6 Com petition assays of В/A precys chimeric receptors
This figure shows fold changes in K, values o f 5-HT, wCPBG, dTC and MDL 7222 for 
the В/A pre-Cys chimeric receptor as compared to 5-НТзд receptors. Kj values were 
obtained as discussed in “Materials and m ethods” . Error bars indicate standard error.
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Chapter 6: Final conclusions
6.1 Role of loop С in 5-НТз ligand binding and function:
The residues identified by this study are shown in a three dimensional manner in 
Figure 6.1. This figures is derived from a preliminary AChBP-based homology model of 
the 5 -HT3R that was constructed in our laboratory. As seen in this picture, loop С which 
belongs to the (+) face o f the binding site is on the surface and forms a cap or lid on the 
binding site. Figure 6.2 illustrates the different binding modes o f  5-HT and mCPBG. 
The results from this study have helped us map the contribution o f amino acids o f this 
loop to the ligand-binding site.
6.1.1 Contribution of loop С residues to the binding site:
We have identified five key residues: E225, F226, 1228, D229 and Y234 in the 
putative “Loop C” region (E225-Y234) o f  the murine 5-HT3AsR using a combination o f 
radioligand binding, electrophysiological and immunofluorescence studies. Our results 
show that residues F225 and Y234 play a dual role in m odulating both ligand binding and 
gating o f 5-HTiR. D229 plays a role in binding to 5-HT (presumably in the desensitized 
state), while I228A mutation solely affects 5-HT mediated gating. The results for D229 
show that not only aromatic, but also negatively charged residues (in addition to E224 
and E236 identified by other laboratories) play an important role in the 5-HT3aR binding
The combination o f biochemical and docking data suggest that the amino group o f 
5-HT is intercalated between F226 and Y234 residues in a cation-л interaction, while the
-O H  group o f 5-HT hydrogen bonds with D229. The agonist mCPBG fits in a similar 
orientation in the binding site, but does not form any interaction with D229. All other 
docking predictions for residues such as E236 from Loop С (which forms a salt bridge 
with amino group o f 5-HT), other Loop В and Loop E residues are also in good 
agreement with existing experimental data.
6.1.2 Differential interaction of Loop С residues with agonists, 5-HT and wCPBG:
Another important finding was that majority o f  the Loop С mutations selectively 
affect affinity o f 5-HT, but not /wCPBG, indicating that these two compounds interact 
differently with this region. This conclusion is also supported by both experimental and 
docking data which show that D229 is involved only in binding to 5-HT, but not 
wCPBG. Similar differences in specificity have been previously reported with the 017 
nAChR Y187F mutation (residue homologous to F226) that specifically alters the affinity 
o f acetylcholine as compared to nicotine (Galzi et al., 1991). Chimeras o f 017 and (X4P2 
nAChRs show that Loop С contributes to the pharmacological specificity (for ach vs. 
nicotine) observed between a? and оцрг Rs. A similar precedence for agonist specificity 
is also seen in previous studies which show that the loop С (pre~M l) segment o f the 5- 
HT3R is responsible for the inter-species differences in potencies o f wCPBG and PBG.
6.1.3 Role of Loop С in gating:
Other than D229A, efficacy comparisons for all other key mutations suggest that 
E225, F 2 2 6 ,1228 and Y234 play a role in gating (or conformational changes after agonist 
binding) o f  the 5-HT?R. According to recently solved ligand bound AChBP structure, the 
residue hom ologous to Y185 o f AChBP (homologous to F226 o f 5 -HT3R) forms a
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hydrogen bond with K149 from the Loop В region after ligand binding, leading to 
significant movement in Loop C. Our data for F226Y R support such a role in gating. The 
residue homologous to K149 o f AChBP is F 179 in the 5-HTiR, Although side chain o f 
F226 can not hydrogen bond with another F residue (F179), a different interaction, (such 
as aromatic) could be forming in 5-HTiR. Such a hypothesis can be tested by future 
studies. M oreover, comparison o f recent ground and active state models o f the 5-НТз 
receptor reveals that the backbone o f 1187 (from Loop B) forms a hydrogen bond with 
the backbone o f S232 from Loop С in the active state (M anuscript in preparation). Thus, 
formation o f such a bond could be aiding the movement o f Loop С after ligand binding.
A role o f loop С region in gating is also supported by the immediate proximity o f 
this loop to the M -l region o f the channel region. Recently, R222, which is adjacent to 
the beginning o f M l region o f the 5-HTiR, was shown to be involved in linking agonist 
binding to channel opening (Hu et al., 2003). This arginine residue has been shown to be 
important in maintaining the stability o f the closed state o f the receptor. The Loop С 
region in GA BA aR has also been shown to play a role in conformational changes 
following agonist binding. The pre-M l region in NM DA receptors has also been shown 
to link agonist binding to channel gating (Krupp et al., 1998). Thus, loop C, by virtue o f 
its proximity to the M -l region may be modulating the gating or signal transduction in 5- 
HT3RS. Loop С residues may also play a role in gating by interacting with loop E 
residues in the binding site, after ligand binding. Recent molecular m odeling studies by 
our collaborator Dr. Bikadi suggest that the Loop С moves closer to loop E after ligand 
binding. Y234 forms a hydrogen bond interaction with Y143 o f  Loop E region after
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ligand binding. The formation o f such an interaction may thus form a critical step in 
channel opening in the 5-HT3AR and explain the altered gating observed for the subtle 
Y234F mutation, which can no longer form a hydrogen bond with Y143. Thus Loop С 
appears to play a role in gating by forming important connections with both loops В and 
E. W hether the opening signal is transduced to the channel through the M l region, the 
Cys-loop & M2-M3 loop connection or some other mechanism remains to be elucidated.
In addition to the aforestated residues that affect gating, the mechanism behind 
the selective effect o f I228A mutation on 5-HT induced gating is unclear. The role 1228 
and other gating residues such as F226 and Y234 can be further explored by single 
channel studies.
6.2 SAR of lerisetron: Importance of N l-B enzyl group
The SAR study using 9 N \ -Benzyl-substituted lerisetron analogs showed that N1- 
substituted analogs have much higher affinity for the 5-HT3 receptor than the 
corresponding N 1-unsubstituted compounds. The results also show' that the benzyl 
interaction has both an electronic and distance component: electron-rich substituents 
(ті-donor ability) increase affinity, whereas electron-deficient substituents decrease 
affinity; lengthening the distance between the aromatic ring and N 1 caused a decrease in 
affinity.
SAR studies o f a 5-HT3R antagonist such as lerisetron have clinical applications; 
since lerisetron is in Phase III clinical trials for treatment o f  chemotherapy-induced 
emesis. Such studies also have implications in new drug design, since data from this class 
o f compounds can be used to develop new 5-FIT3R antagonists.
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6.3 Role of 5 -HT3B subunit in 5-НТздв R structure
The results from the pilot study involving 5-Н Тз A and В subunit chimeras 
suggest that the В subunit has important assembly signals and/or intersubunit contact 
points that play a critical role in formation o f cell surface receptors. Such signals seem to 
spread across the entire 5-НТз В aminoterminal, rather than selected areas. Therefore, 
localization o f these signals is difficult, since even a small substitution in a stretch of 
amino acids ablates cell surface expression. This study concludes that in addition to the 
transmembrane region, the 5-HTjB aminoterminal also bears important assembly signals.
6.4 M ethodology development for mutagenesis reactions
During the course o f the work described in this thesis, newer techniques were 
developed for faster and more reliable mutant synthesis. Several changes in 
oligonucleotide design [length, melting temperature (Tm)] were tested. Similarly various 
reaction conditions o f PCR (such as type o f polymerase, length o f each step in PCR etc) 
were altered to obtain optimal results. As a result o f  these changes, point mutants can 
now be generated relatively quickly (in as little as 1 week) and with higher efficiency 
(50-75% colonies tested carry the desired mutation). Due to these advances, a stretch o f 
a region in a protein can be sequentially mutated in a relatively short span o f  time.
New protocols were also established in the laboratory for epitope tagging (Flag, 
myc, his and GFP tagging) o f various cDNAs. Protocols for immunofluorescence assays 
for localization o f  epitope tagged receptors expressed in mammalian cells were also 
established during the course o f this work.
6.5 Final conclusions and future implications
Results from this study show that amino acids in the Loop С region play a role in 
both ligand binding and gating. Results from this study present an emerging picture o f 
differential interactions o f  5-HT and raCPBG with the Loop С region o f the 5-HT3R. 
Although it was known that the Loop С region is responsible for the interspecies 
differences in potencies o f these agonists, the molecular details o f the interactions o f 
these agonists with this region o f the 5-HT3R were largely unexplored. This study shows 
that these two structurally different agonists act via different binding and gating 
mechanisms with the 5-HT3 receptor, and that these differences are minor, differing by 
only few amino acids. These results thus provide a novel way o f  finely modulating the 5- 
HT3R. Analogs o f wCPBG and 5-HT can be evaluated in future to design new agonists 
that interact with different conformations o f the receptor. Results from the studies 
described here also help in refining the existing 5-НТзR homology models and in the 
development o f  open and closed state models. Similar studies can also be carried out in 
other members o f the Cys-loop LGIC family. Results from this study can be applied 
towards better drug design for both 5-HT3 agonists and antagonists. Such agonists can act 
as useful tools to understand receptor mechanism, especially since very few 5-HT3R 
specific agonists are currently available.
Data from SAR studies o f antagonists is valuable in designing more effective 
drags. Biochemical data from new antagonists is also valuable in the development of 
closed state models o f  the 5-HT3R.
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Figure 6.1: An AChBP-based homology model of the extracellular domain of the 5- 
H T,aR.
This figure shows an AChBP-based homology model o f the 5-HT3AR extracellular 
domain. As indicated by the box, the ligand-binding cleft is at the interface between two 
subunits, subunit 1 and 2. Subunit 1 contributes to the principal or (+) face o f the binding 
cleft and subunit 2 contributes to the (-) face. The (+) face is formed by loops A-C, 
whereas the (-) face is formed by loops D-F. Loop С forms a lid across the binding cleft 
as shown in the model.
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Figure 6.2 Binding modes of 5-HT and /wCPBG with the murine 5-HT3AR
This figure shows a close-up o f the loop С region o f the binding site. The binding modes 
o f 5-HT and wCPBG are shown. The key amino acids identified by the mutagenesis 
study are indicated. Please see chapter 3 for details o f ligand docked models o f the 5- 
HT3AR.
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